

## QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)

### MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

*As used in this management's discussion and analysis of financial condition and results of operations (this "MD&A"), unless the context indicates or requires otherwise, all references to the "Company", "Quantum", "Quantum BioPharma", "we", "us" or "our" refer to Quantum BioPharma Ltd., together with our subsidiaries, on a consolidated basis as constituted on December 31, 2025.*

*This MD&A for the three months and years ended December 31, 2025, 2024 and 2023 should be read in conjunction with the Company's audited consolidated financial statements and the accompanying notes for the years ended December 31, 2025, 2024 and 2023 (the "financial statements"). The financial information presented in this MD&A is derived from the financial statements which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board. All amounts are in United States dollars except where otherwise indicated.*

*This MD&A is dated as of March 26, 2026.*

#### **About Quantum BioPharma Ltd.**

Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) ("Quantum" or the "Company") is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development.

Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) ("Lucid-MS"). Lucid-MS is a patented new chemical entity that has been shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.

The Company has also licensed its proprietary formulation, Unbuzzd, a blend of natural ingredients, vitamins, and minerals designed to support liver and brain function for the purpose of quickly relieving individuals from the effects of alcohol consumption. On July 31, 2023, the Company entered into an exclusive intellectual property license agreement (the "IP License Agreement") with Celly Nutrition Corp. ("Celly"), which changed its name to Unbuzzd Wellness Inc. ("Unbuzzd") effective May 23, 2025. The agreement grants Unbuzzd the rights to this formulation and certain associated trademarks for consumer product development and marketing.

In exchange for these rights, Quantum received 200,000,000 common shares of Unbuzzd (following a 2:1 share split) and an anti-dilution warrant certificate, initially representing a 34.66% ownership interest. The Company is also entitled to license fees and royalties on revenue generated from products created using the licensed technology. In November 2023, through a Plan of Arrangement, the Company distributed a portion of its Unbuzzd shares (45,712,529) to its own shareholders. As a result of this distribution and subsequent dilution, as of December 31, 2025, the Company held a 19.84% (December 31, 2024 – 22.95%) ownership interest in Unbuzzd. Consequently, the consolidated financial statements incorporate the assets, liabilities, results of operations, and cash flows of Unbuzzd for the years ended December 31, 2025, and 2024.

Furthermore, on July 31, 2023, the Company entered into a loan agreement with Unbuzzd for gross proceeds of C\$1,000,000, which was amended on April 3, 2024, for an additional C\$300,000. The loan accrues interest at 10% per annum and matures on July 31, 2026. In addition to the Unbuzzd program, the Company continues its internal research and development of novel formulations for the treatment of alcohol misuse for potential application in hospitals and other medical practices. The Company also maintains selective R&D programs for inflammatory diseases (FSD-PEA) and depression (Lucid-PSYCH), though these initiatives remain secondary priorities.

In addition to its core biopharmaceutical activities, the Company had historically maintained a portfolio of strategic residential investments through its wholly owned subsidiary, FSD Strategic Investments Inc. ("FSD Strategic Investments"), which focused on issuing loans secured by residential real estate properties. During the year ended December 31, 2025, the entire portfolio of these loan receivables was sold to a related party. As of December 31, 2025, the Company no longer holds any loans secured by residential properties.

Finally, the Company expanded its corporate treasury management function to include investments in cryptocurrencies. This initiative is aligned with the Company's financial diversification goals and supports its long-term strategic objectives.

On August 15, 2024, the Company consolidated its class A multiple voting shares ("Class A Multiple Voting Shares") and class B subordinate voting shares ("Class B Subordinate Voting Shares") on a 65:1 basis and changed its name to "Quantum

BioPharma Ltd." with a new trading symbol "QNTM" on both the Nasdaq Stock Market LLC ("Nasdaq") and the Canadian Securities Exchange (the "CSE").

The Class B Subordinate Voting Shares are "restricted securities" within the meaning of such term under applicable Canadian securities laws, as these securities do not carry equal voting rights as compared with the Class A Multiple Voting Shares. For more information, please refer to the section titled "Outstanding Share Data".

The Company's registered office is located at 1 Adelaide Street East, Suite 801, Toronto, Ontario, M5C 2V9, and its telephone number is +1-833-571-1811.

## **FORWARD-LOOKING INFORMATION**

*This MD&A contains forward-looking statements within the meaning of applicable securities laws. These statements, which are not historical facts, often include terms such as "plans," "expects," "estimates," "intends," or similar language and refer to future events, business prospects, or results. Forward-looking statements are based on assumptions made as of the date of this MD&A, and actual outcomes may differ significantly due to risks and uncertainties. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding the future of the Company, and are based on certain assumptions that the Company has made in respect thereof as of the date of this MD&A. The Company cannot give any assurance that such forward-looking statements will prove to have been correct.*

*Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it believes the expectations and material factors and assumptions reflected in these forward-looking statements are reasonable as of the date hereof, there can be no assurance that these expectations, factors and assumptions will prove to be correct, and these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Key risks affecting these statements include uncertainties in the development and commercialization of our pharmaceutical products (such as Lucid-MS and PEA), reliance on Unbuzzd Wellness, our licensing partner to commercialize Unbuzzd, unpredictable clinical trial results, regulatory uncertainties, volatility in our crypto-asset holdings, challenges in securing adequate capital, the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of Lucid; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of Lucid; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the Company's drug product candidates; the potential inability to obtain or maintain intellectual property protection for the drug product candidates; and competition from better-funded companies and other risks described in our Annual Report on Form 20-F for our fiscal year ended December 31, 2025, filed with the SEC on March 26, 2026.*

*This list of risk factors contained herein and in our Annual Report on Form 20-F should not be construed as exhaustive. Readers are cautioned that events or circumstances are not guarantees of performance and could cause results to differ materially from those predicted, forecasted or projected. The forward-looking statements contained in this document speak only as of the date of this document. Quantum does not undertake any obligation to publicly update or revise any forward-looking statements or information contained herein, except as required by applicable laws. Additional information relating to Quantum can be found on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca) and on EDGAR at [www.sec.gov](http://www.sec.gov).*

## **OVERVIEW**

### **1. Corporate Structure**

Effective November 1, 1998, pursuant to the amalgamation of Olympic ROM World Inc., 1305206 Ontario Company, 1305207 Ontario Inc., Century Financial Capital Group Inc. and Dunberry Graphic Associates Ltd. in accordance with the provisions of the *Business Corporations Act* (Ontario) (the "OBCA"), the Company was formed.

Effective May 24, 2018, following receipt of shareholder approval at the March 15, 2018 annual and special meeting of the proposed amendments to the Company's articles, and pursuant to the articles of amendment, the Company changed its name to "FSD Pharma Inc." and the capital structure of the Company was reorganized to create a new class of Class A multiple voting shares (the "Class A Multiple Voting Shares"), amended the terms of and re-designated the existing common shares as Class B subordinate voting shares (the "Class B Subordinate Voting Shares"), and eliminate the existing non-voting class A preferred shares and non-voting class B preferred shares.

Effective May 29, 2018, the Class B Subordinate Voting Shares commenced trading on the CSE under the trading symbol "HUGE".

Effective October 16, 2019, the Company completed a 201:1 consolidation.

On January 9, 2020, the Class B Subordinate Voting Shares commenced trading on the Nasdaq under the trading symbol "HUGE".

On August 15, 2024, the Company completed the 2024 Consolidation and changed its name to "Quantum BioPharma Ltd.". In connection with the name change, the Company's trading symbol was changed to "QNTM" on both the Nasdaq and CSE.

As at the date of this report, the Company is a reporting issuer in each of the provinces and territories of Canada. The Company's registrar and transfer agent is Marrelli Trust Company Limited. The Company's agent for service in the United States is CT Company, 28 Liberty Street, New York, New York 10005.

## **2. Business Segments**

The Company's operations were organized into two primary business segments: Biopharmaceutical and Strategic Investments. The Biopharmaceutical segment is dedicated to developing therapies for neurodegenerative, inflammatory, and metabolic disorders, as well as alcohol misuse. Key initiatives include advancing Lucid-MS, a patented clinical-stage compound targeting myelin restoration in multiple sclerosis, and monetizing unbuzzd™, a licensed alcohol-recovery formulation, through a royalty-generating IP License Agreement with Unbuzzd Wellness and its U.S. affiliate.

Through its subsidiary FSD Strategic Investments, the Company maintained a portfolio of residential real estate-backed loans, secured by first or second mortgages, to generate stable cash flow and capital returns. During the year ended December 31, 2025, the entire portfolio of these loan receivables was sold to a corporation owned by the CFO of the Company. As of December 31, 2025, the Company no longer holds any loans secured by residential properties. Therefore, this business segment ceased to exist as of December 31, 2025, and will no longer be reported in future periods.

Separately, the Company expanded its corporate treasury management to include cryptocurrency investments, aligning with its strategy for financial diversification and long-term growth.

As at the date of this report, the Company currently has the following subsidiaries:

- (i) FSD BioSciences Inc. ("FSD Biosciences"), which is wholly owned by the Company and incorporated under the laws of the State of Delaware;
- (ii) Prismic Pharmaceuticals Inc. ("Prismic"), which is wholly owned by the Company and incorporated under the laws of the State of Arizona;
- (iii) FV Pharma Inc. ("FV Pharma"), which is wholly owned by the Company and incorporated under the OBCA;
- (iv) Lucid Psycheceuticals Inc., which is wholly owned by the Company and incorporated under the OBCA;
- (v) FSD Strategic Investments Inc., which is wholly owned by the Company and incorporated under the OBCA;
- (vi) FSD Pharma Australia Pty Ltd. ("FSD Australia"), which is wholly owned by the Company and incorporated under the laws of Australia;
- (vii) Unbuzzd Wellness Inc., formerly Celly Nutrition Corp, an entity controlled by the Company and incorporated under the British Columbia Business Corporations Act. Celly Nutrition Corp. changed its name to "Unbuzzd Wellness Inc.", effective May 23, 2025.
- (viii) Huge Biopharma Australia Pty Ltd ("Huge Biopharma"), which is wholly owned by the Company and incorporated under the laws of Australia.

## **IMPORTANT EVENTS IN THE DEVELOPMENT OF THE COMPANY'S BUSINESS IN FISCAL YEARS 2024, AND 2025, TO THE DATE OF THIS MD&A REPORT.**

January 4, 2024: the Company's registration statement on Form F-3 (File No. 333-276264) filed under the Securities Act with the SEC containing a base shelf prospectus with the SEC on December 22, 2023 (the "U.S. Base Prospectus") was declared

effective (the “January 2024 Registration Statement”). The January 2024 Registration Statement qualifies the offer, and sale, from time to time of Class B Subordinate Voting Shares up to an aggregate amount of US\$50,000,000, subject to limitations, as applicable, under Form F-3. The January 2024 Registration Statement is available for use by the Company until the earlier of January 4, 2027. The terms of any Securities to be offered under the January 2024 U.S. Base Prospectus will be specified in a prospectus supplement, which will be filed with the SEC in connection with any such offer.

January 8, 2024: the United States District Court for the Southern District of Florida dismissed the Company’s request for a motion to dismiss the complaint filed against it by GBB Drink Lab, Inc. (“GBB”).

January 24, 2024: the Company entered into an agreement with SBS Intl Group LLC. (“SBS”) to assist the Company in enhancing its market awareness and foster productive, continuing dialogues with shareholders and other market participants. The agreement granted SBS 1,539 Options with an exercise price of C\$68.25 and expiry date of January 24, 2026. As of the date of this report, this agreement has been terminated, and all share-based compensation forfeited.

January 24, 2024: the Company entered into an agreement with Draper, Inc. (“Draper”) and Carriage House Capital, Corp. (“Carriage House”) to assist the Company on in enhancing its market awareness and foster productive, continuing dialogues with Shareholders and other market participants. The agreement granted Draper and Carriage 5,385 Options each with the exercise price of C\$68.25 and expiry date of January 24, 2026. As of the date of this report, this agreement has been terminated, and all share-based compensation forfeited.

January 29, 2024: the Company appointed Dr. Sanjiv Chopra, MD to the Board to replace Nitin Kaushal.

February 6, 2024: the Court of Appeal for Ontario (“ONCA”) affirmed the ONSC’s judgement in the amount of C\$2.8 million plus C\$175,000 against Dr. Raza Bokhari. An additional C\$5,000 in costs was awarded to the Company by the ONCA in respect of Dr. Raza Bokhari’s failed motion for leave to appeal.

February 6, 2024: the Company incorporated Huge Biopharma to conduct research related to Lucid-MS in Australia.

February 11, 2024: the Company engaged MZHCI, LLC, an MZ Group Company (“MZ”) to lead a comprehensive strategic investor relations and financial communications program across all key markets (the “MZ Agreement”). Pursuant to the MZ Agreement, MZ is paid US\$10,000 per month. Either party has the right to terminate the MZ Agreement upon fifteen days’ notice. As of the date of this report, the MZ Agreement remains in effect.

February 16, 2024: the Company entered into an at-the-market offering agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company, at its discretion, may offer and sell, from time to time, through Wainwright as sales agent, Class B Subordinate Voting Shares, having an aggregate offering price of up to US\$11,154,232 (the “ATM Offering”). A cash commission of 3.0% on the aggregate gross proceeds raised under the ATM Offering is payable to Wainwright in connection with its services. The ATM Offering was made in the United States pursuant to the January 2024 Registration Statement and the prospectus supplement dated February 16, 2024, and as amended pursuant to the Amendment No. 1 to the prospectus supplement dated August 26, 2024 (together with January 2024 Registration Statement, the “ATM U.S. Prospectus”) filed with the SEC.

- Sales of the Class B Subordinate Voting Shares under the ATM U.S. Prospectus will and have been made in transactions that are deemed to be “at-the-market” offering as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, (the “Securities Act”) including sales made directly on or through the Nasdaq. The Class B Subordinate Voting Shares will be distributed at the prevailing market prices at the time of each sale. As a result, prices may vary between purchasers and during the period of distribution. No Class B Subordinate Voting Shares in the ATM Offering will be sold on the CSE or any other trading market in Canada.
- The volume and timing of sales, if any, will be determined at the sole discretion of the Company’s management and in accordance with the terms of the ATM Agreement. If the Company chooses to sell Class B Subordinate Voting Shares under the ATM Offering, the Company intends to use the net proceeds of the ATM Offering (i) to fund various clinical studies, trials and development programs, (ii) to fund R&D, and (iii) for general corporate purposes and working capital.
- From February 16, 2024, through December 31, 2024, the Company sold an aggregate of 1,384,783 Class B Subordinate Voting Shares on a post-consolidation basis, pursuant to the ATM U.S. Prospectus for gross proceeds of approximately US\$11,746,730.

February 19, 2024: Huge Biopharma entered into an agreement with Ingenu CRO Pty Ltd. ("Ingenu") to conduct the METAL-1 TRIAL.

February 28, 2024: the Company announced the settlement of an aggregate of US\$492,135 of amounts owing to arm's length creditors through the issuance of 8,385 Class B Subordinate Voting Shares at the deemed price of US\$0.903 per Class B Subordinate Voting Share.

March 11, 2024: the Company, through Huge BioPharma, submitted a Clinical Trial Application ("CTA") or a planned Phase-1b clinical trial to Assess the Safety and Efficacy of unbuzzd™ in Healthy Volunteers in an Induced State of Alcohol Intoxication ("METAL-1 TRIAL") to a human ethics review committee ("HREC") in Australia.

March 26, 2024: Huge Biopharma entered into agreement with Ingenu to conduct a trial in connection with Lucid-21-302.

March 31, 2024: the principal amount of the C\$1,000,000 million loan that the Company advanced to Unbuzzd Wellness (the "Unbuzzd Loan") was increased by C\$300,000.00, pursuant to the amendment to the Loan Agreement between the Company and Unbuzzd Wellness, dated as of April 3, 2024, with an effective date of March 31 2024. No retroactive interest was to be charged on the increased amount. Thus, the total principal amount of the Unbuzzd Loan equates to C\$1,300,000.00 as of December 31, 2025. The interest rate per annum remained unchanged.

April 5, 2024: the Company received a written notification (the "April 2024 Nasdaq Notification Letter") from Nasdaq that the Company was not in compliance with the minimum bid price requirement set forth in Nasdaq's Listing Rule rules for continued listing on the Nasdaq. The April 2024 Nasdaq Notification Letter was a deficiency notice, not a delisting notice, and did not affect the trading of the Class B Subordinating Voting Shares. Nasdaq Listing Rule 5550(a)(2) requires securities listed on Nasdaq to maintain a minimum bid price of US\$1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business day. The Class B Subordinate Voting Shares traded at a price of less than \$1.00 per share for 30 consecutive business days between from February 22 to April 4, 2024. The Company was given until October 2, 2024, to regain compliance by maintaining a closing bid price of at least \$1.00 for 10 consecutive business days. The Company regained compliance on September 6, 2024.

April 22, 2024: Unbuzzd Wellness announced a strategic partnership with BevSource, a provider of beverage development, production and operations solutions.

April 24, 2024: the Company entered into an agreement with Applied Science and Performance Institute ("ASPI") in Tampa, Florida, to conduct a "A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Assess the Safety and Efficacy of unbuzzd™ in Healthy Volunteers in an Induced State of Alcohol Intoxication (METAL-2 TRIAL)".

April 25, 2024: Unbuzzd Wellness announced its partnership with Six+One, a branding, advertising and production agency.

May 7, 2024: the Company announced the submission to the HERC in Australia of a trial entitled "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants."

May 16, 2024: Unbuzzd Wellness announced its newly designed packaging and logo.

May 22, 2024: the Company entered into an investor relations services agreement with IR Agency LLC ("IR Agency"). Pursuant to the agreement, IR Agency agreed to communicate information about the Company to the financial community including, but not limited to, creating company profiles, media distribution and building a digital community with respect to the Company for a period of one month beginning on May 28, 2024, in exchange for a fee of US\$245,000. At the date of this report, the Company discontinued its engagement with IR Agency.

May 28, 2024: the Company submitted a clinical trial protocol the Institutional Review Board in the United States for its METAL-2 TRIAL.

June 11, 2024: the Company entered into an option agreement with the University of Southern California ("USC") to evaluate dietary supplement technology for commercialization (the "USC Agreement"). The USC Agreement allowed the Company to exclusively evaluate its novel technology for a 6-month term. At the end of this USC Agreement, the Company decided not to extend the USC Agreement.

June 27, 2024: the Company received approval from the HREC in Australia for its trial in connection with Lucid 21-302.

June 27, 2024: the United States District Court for the Eastern District of Pennsylvania granted judgement in favor of the Company in its case against Dr. Raza Bokhari.

June 28, 2024: the Company retained the services of Totaligent, Inc. (“Totaligent”), a market awareness firm with 25 years of experience and a 32-million investor database, for a 30-day contract valued at US\$30,000, ending July 28, 2024, unless renewed, with both parties maintaining a 5-day termination notice option. As at today’s date, the Company discontinued its engagement with Totaligent.

August 13, 2024: the Company entered into an agreement with Ingenu to conduct a clinical study to observe and quantify disease progression in patients with primary progressive multiple sclerosis. This study will facilitate a future phase 2 clinical trial with Lucid-MS. This agreement is still in place.

August 14, 2024: the Unbuzzd Wellness IP License Agreement (i) was amended to add the U.S. subsidiary of Unbuzzd Wellness, as a licensee to the Unbuzzd Wellness IP License Agreement, effective as of the August 14, 2024, and granted the U.S. subsidiary of Unbuzzd Wellness exclusive global rights to commercialize the Licensed IP from August 14, 2024, (ii) noted that Unbuzzd Wellness became the sole and exclusive owner of the unbuzzd™ trademark pursuant to an intellectual property purchase agreement with the Company dated October 2, 2023, and amended the definition of the Licensed IP in the Unbuzzd Wellness P License Agreement to exclude unbuzzd™ any time after the unbuzzd™ trademark assignment date, and (iii) confirmed that Unbuzzd Wellness retained an exclusive global license to commercialize the Licensed IP since July 31, 2023, the effective date of the Unbuzzd Wellness License Agreement. All other terms in the Unbuzzd Wellness License Agreement remained substantially the same.

August 15, 2024: the Company completed the 2024 Consolidation and changed its name to “Quantum BioPharma Ltd.”. In connection with the name change, the Company’s trading symbol was changed to “QNTM” on both the Nasdaq and CSE. The new CUSIP and ISIN for the Class B Subordinate Voting Shares were changed to 74764Y205 and CA74764Y2050, respectively. After giving effect to the 2024 Consolidation, the Class B Subordinate Voting Shares were reduced from 84,531,149 to approximately 1,300,727 Class B Subordinate Voting Shares and the Class A Multiple Voting Shares were reduced from 72 to 2 Class A Multiple Voting Shares. No fractional Class A Multiple Voting Shares and Class B Subordinate Voting Shares were issued in connection with the 2024 Consolidation. Instead, all fractional Class A Multiple Voting Shares or Class B Subordinate Voting Shares were rounded up to the nearest whole number. The exercise price and/or conversion price and number of Class B Subordinate Voting Shares issuable under any of the Company’s outstanding convertible securities were proportionately adjusted in connection with the 2024 Consolidation.

August 15, 2024: the Company closed a non-brokered private placement and issued four (4) Class A Multiple Voting Shares at a price of C\$18.00 per Class A Multiple Voting Share for aggregate gross proceeds of C\$72.00 (the “August 2024 Class A Multiple Voting Share Private Placement Offering”). Xorax Family Trust, a trust of which Zeeshan Saeed, the Chief Executive Officer (“CEO”) and Co-Executive Chairman of Quantum BioPharma is a beneficiary (“Xorax”), and Fortius Research and Trading Corp., a corporation controlled by Anthony Durkacz, a Co-Executive Chairman of Quantum BioPharma, is a director (“Fortius”), purchased all the Class A Multiple Voting Shares issued pursuant to the August 2024 Class A Multiple Voting Share Private Placement Offering. The participation by such insiders is considered a “related-party transaction” within the meaning of MI 61-101.

August 23, 2024: the Company canceled an aggregate of 47,358 Options (“August 2024 Options”) to purchase Class B Subordinate Voting Shares, which were previously granted to board members, advisory board members, employees, advisors and consultants of the Company (each a “August 2024 Option Participant”). Management reviewed the Company’s outstanding August 2024 Options and determined that certain August 2024 Options granted to such August 2024 Option Participants under the Company’s Equity Incentive Plan, at exercise prices, ranging from C\$84.50 to C\$189.15 per Class B Subordinate Voting Share, no longer represented a realistic incentive to motivate the August 2024 Option Participants.

August 23, 2024: the Company announced the grant of RSUs (August 2024 RSUs”) pursuant to the Equity Incentive Plan. The Company granted an aggregate of 32,690 August 2024 RSUs to certain officers, directors, and employees of the Company. Each August 2024 RSU granted vests the earlier of: (i) one year; and (ii) the successful implementation of the Lucid-MS MAD study conducted by Ingenu, subject to acceleration in the event of a takeover bid or change of control.

August 23, 2024: the Board authorized and approved bonuses in the amount of C\$450,000 to each of Anthony Durkacz, Zeeshan Saeed and Donal Carroll, officers of the Company, (together, the “Executives”) pursuant to the terms and conditions of certain executive agreements entered into between the Company and each of the Executives (together, the “Executive Agreements”). Pursuant to the terms and conditions of the respective Executive Agreements, each Executive was entitled to certain annual bonuses, based on the Executive and Company meeting certain performance milestones, calculated on the basis of 70% of the

respective Executive's base salary for the second year of employment and 80% of the respective Executive's base salary for the third year of employment, which equates to a bonus payment of C\$210,000 and C\$240,000, respectively, for each Executive for each year of service (each, a "August 2024 Bonus Payment"). Subject to compliance with CSE policies, the Company and Executives determined that to preserve the Company's cash, it settled the August 2024 Bonus Payments into Class B Subordinate Voting Shares at a deemed price of C\$5.44 per Class B Subordinate Voting Share.

August 26, 2024: the Company filed an amendment to the ATM U.S. Prospectus.

August 30, 2024: Donal Carroll assumed the role of Chief Financial Officer, and Nathan Coyle assumed the role of Controller. In addition, the Company appointed Jason Sawyer as the Head of Finance and Mergers and Acquisitions.

August 30, 2024: Unbuzzd Wellness launched unbuzzd™ Clear Eyed Citrus Powder grab-and-go stick packs on Amazon.com.

September 6, 2024: the Company regained compliance with Nasdaq's continued listing requirements after receiving the April 2024 Nasdaq Notification Letter. See "April 5, 2024" for more information.

September 6, 2024: the Company completed debt settlements in the amount of C\$450,000 with the Executives to preserve the Company's cash through the issuance of 248,160 Class B Subordinate Voting Shares, at a deemed price of C\$5.44 per Class B Subordinate Voting Share.

September 6, 2024: the Company granted an aggregate of 12,500 Options (the "September 2024 Options"), and an aggregate of 7,500 RSUs (the "September 2024 RSUs") to a director and certain consultants of the Company. Each September 2024 Option is exercisable at a price of C\$5.60 per Class B Subordinate Voting Share, expires two years from the date of grant and vest in one-third increments with the first batch vesting immediately and the remaining two thirds vesting equally on the 6 month and 12-month anniversary of the date of grant. Each September 2024 Option is exercisable to purchase one Class B Subordinate Voting Share. Each September 2024 RSU granted vested immediately.

September 6, 2024: the Company canceled an aggregated of 7,692 warrants to purchase Class B Subordinate Voting Shares, which were previously granted to a board member. Management reviewed the Company's outstanding warrants and determined that the warrants granted to such individual at an exercise price of C\$97.50 per Class B Subordinate Voting Share no longer represented a realistic incentive to motivate such individual.

September 13, 2024: the Company closed a non-brokered private placement and issued six Class A Multiple Voting Shares at a price of C\$6.00 per Class A Multiple Voting Share for gross proceeds of C\$36.00 (the "September 2024 Class A Multiple Voting Share Private Placement Offering"). Xorax and Fortius purchased all the Class A Multiple Voting Shares issued pursuant to the September 2024 Class A Multiple Voting Share Private Placement Offering. The participation by such insiders was considered a "related-party transaction" within the meaning of MI 61-101. The Company relied on exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in respectively, sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related party participation in the September 2024 Class A Multiple Voting Share Private Placement Offering as neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it involved the related parties, exceeded 25% of the Company's market capitalization (as determined under MI 61-101). Fortius, Xorax and the Company entered into a Shareholder Agreement dated September 13, 2024 ("Shareholder Agreement"), which prohibits unauthorized transfers of the Class A Multiple Voting Shares. See "Item 7. Major Shareholders and Related Party Transactions B. Related Party Transactions – Shareholder Agreement" in the Company's Annual Report on Form 20-F filed with the SEC on March 28, 2025., as amended.

September 27, 2024: the Company announced the grant of 29,500 Options to certain directors, officers, employees, and consultants (the "September 2024 Options"). Each September 2024 Option granted vests immediately and is exercisable at a price of C\$5.25 for a period of two years from the issue date. A director of the Company received 7,500 of the September 2024 Options, and thus, the foregoing as it applies to such party represents a related-party transaction under MI 61-101. However, the transaction was exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of the subject matter of the transaction nor the consideration exceeds 25% of the Company's market capitalization.

September 27, 2024: the Company announced it has retained the services of Cambridge Consultants Inc. ("Cambridge") for \$35,000, TD Media LLC dba Life Water Media ("LWM") for \$75,000, and King Tide Media LLC ("KTM") for \$50,000. As at today's date, the Company has discontinued its engagement with Cambridge, LWM, and KTM pursuant to this agreement.

October 7, 2024: the Company announced that Unbuzzd U.S. signed a master distribution agreement with FUSION.

October 20, 2024: On October 20, 2024, the Company filed a complaint in the U.S. District Court for the Southern District of New York against CIBC World Markets, Inc., RBC Dominion Securities Inc., and John Does 1-10.

October 29, 2024: the Company engaged Agoracom Independent Trading Group (“Agoracom”) for C\$25,000, Buyins, Inc. (“Buyins”) for US\$15,000, and Stockjock.com LP (“Stockjock”) for US\$15,000, to enhance market awareness and shareholder engagement, following a capital review and in compliance with CSE policies. Agoracom and ITG agreements require 30 days’ termination notice, while Buyins and Stockjock require 10 days’ notice. As of the date of this report, the Company remains engaged in these agreements.

October 31, 2024: The Company further decreased its outstanding debt to a creditor through a debt settlement agreement involving cash payments. Previously reported on the balance sheet at approximately US\$611,000, the debt has been reduced to around US\$211,000, reflecting a substantial reduction of approximately US\$400,000.

November 5, 2024: the Company settled its total outstanding debt to a creditor, which was previously reported on the balance sheet at approximately US\$278,000. The Company and the creditor reached a debt settlement agreement, whereby the creditor would be compensated by an external party to the Company.

December 5, 2024: the Company announced it intended to complete a non-brokered private placement offering (the “December 2024 Offering”) of up to 5,000 convertible debenture units of the Company (each, a “December 2024 Debenture Unit”) at a price of C\$1,000 per Debenture Unit. Each December 2024 Debenture Unit consists of (i) one convertible debenture having a face value of C\$1,000.00 (each a “December 2024 Debenture”); and (ii) 80 Class B Subordinate Voting Share purchase warrants (each a “December 2024 Warrant”) exercisable for 80 Class B Subordinate Voting Shares. The December 2024 Debentures matures on the date that is 36 months from the date of issuance and bears interest at a rate of 1.25% per month, beginning on the date of issuance and is payable in cash on the last day of each calendar quarter. The principal sum of the December 2024 Debenture, or any portion thereof, and any accrued but unpaid interest, may be converted into Class B Subordinate Voting Shares at a conversion price of C\$6.25 per Class B Subordinate Voting Share. Each December 2024 Warrant shall entitle the holder to acquire one additional Class B Subordinate Voting Share at a price of C\$7.00 per Class B Subordinate Voting Share, for a period of five (5) years from the date of issuance. The December 2024 Debenture contained normal course default provisions, and a default if the volume weighted average price of the Class B Subordinate Voting Shares on the Canadian Securities Exchange is at or below C\$5.3125 for any period of 10 consecutive trading days (the “VWAP Default”). The December 2024 Debenture and December 2024 Warrant contain a provision that prevents conversion or exercise, as applicable, if the holder’s interest in the Company would exceed 9.99%. The Company shall have a right to prepay or redeem a part or the entire principal amount of the December 2024 Debenture for a cash amount equal to the sum of all payments of interest on the December 2024 Debenture, that would be due through to the maturity date (the “Prepayment Penalty”). In the event the holder converts the entire amount owing on the December 2024 Debenture within 6 months of the issuance date, the holder shall be entitled to receive a cash amount equal to half the sum of all payments of interest on the December 2024 Debenture that would be due through to the maturity date, or at the option of the holder Class B Subordinate Voting Shares at the conversion price (the “Conversion Bonus”). The Company would use proceeds from the December 2024 Offering for the ongoing development of the Company’s business model and for general working capital purposes.

December 10, 2024: the Company’s safety review committee recommended commencing dosing of the second cohort in its trial entitled “A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants.”

December 13, 2024: the Company closed an initial tranche of the December 2024 Offering and issued 500 December 2024 Debenture Units for C\$500,000. See “December 5, 2024” above for more details on the December 2024 Offering.

December 18, 2024: the Company entered into an investor relations services agreement with Enterprise Canada Inc. (“Enterprise”). Pursuant to the agreement (“Enterprise Agreement”), Enterprise has been engaged for an indefinite period. The Enterprise Agreement is structured in three phases, with C\$10,000 paid to Enterprise at the start of phase 1, C\$2,500 on the completion of phase 2, and C\$5,000 due monthly as a public relations retainer (phase 3). Enterprise will be assisting the Company with its public relations strategy, which includes developing the Company’s narrative, key messages, and pitching strategies with identified targets. As of the date of this report, the parties remain engaged in the Enterprise Agreement.

December 20, 2024: the Company closed the second tranche of the December 2024 Offering and issued 500 December 2024 Debenture Units for C\$500,000. See “December 5, 2024” above for more details on the December 2024 Offering.

December 20, 2024: the Company purchased US\$1,000,000 of Bitcoin and other cryptocurrencies as part of its strategic efforts.

December 24, 2024: the Company entered into a prepaid forward purchase agreement (“Sports Coat Prepaid Purchase Agreement”) with Sports Coat LLC (“Sports Coat”), whereas Sports Coat agreed to provide financing of US\$1,000,000 to the Company as consideration for purchasing proceeds of the litigations (the “Litigation Proceeds”) which includes any of the following involving: (i) claims relating to market manipulation / securities / commodities / exchanges brought by or on behalf of Quantum Biopharma Ltd. or any related entity; or (ii) Dr. Raza Bokhari. Per terms stated in the Sports Coat Prepaid Purchase Agreement, the Company is not obligated to repay US\$1,000,000 to Sports Coat if no proceeds are realized from the lawsuit as the financing is considered non-recourse. Sports Coat bears risk of loss in the event of non-collection of the Litigation Proceeds. The Sports Coat Prepaid Purchase Agreement does not have a predefined repayment schedule, or specified due date, and the Company has not generally pledged its assets as collateral to ensure repayment.

January 7, 2025: the Company was approved to dual list its shares on Upstream, a MERJ Exchange market and global securities trading application. The dual listing on Upstream is designed to provide the Company the opportunity to access a global investor base outside of the U.S. that can trade using a credit/debit card, PayPal, USD, or USDC (a stable coin pegged to the USD); unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in the Company. The Upstream market is open to non-U.S. investors 7 days a week 20 hours a day, Monday to Sunday: 10:00am to 06:00am UTC+4 (1:00am to 9:00pm EST). Traders on Upstream’s smart-contract powered market will experience real-time trading and settlement, and a transparent orderbook which does not permit common market manipulations.

January 14, 2025: the Class B Subordinate Voting Shares started trading on the MERJ Exchange at 10:00am ET under the ticker symbol “QNTM”. See “*January 7, 2025*” above for more information.

January 20, 2025: the Company closed the third tranche of the December 2024 Offering and issued 1,480 December 2024 Debenture Units for aggregate gross process of C\$1,480,000. This third tranche was completed under amended terms, including a reduced conversion price of C\$4.85 per share, an increased warrant ratio of 103.093 Warrants per Debenture Unit, and a reduced exercise price of C\$5.25 per Warrant share. On February 7, 2025, the investor converted a partial amount of this Debenture into an aggregate of 152,577 shares of the Company’s Class B Subordinate Voting Shares. On February 26, 2025, the investor converted the remaining amount of the Debenture into an aggregate amount of 221,237 shares of the Company’s Class B Subordinate Voting Shares. Thus, the total amount of Class B Subordinate Voting Shares converted under this Debenture was 373,814. See “*December 5, 2024*” above for more details on the December 2024 Offering.

January 24, 2025: the Company sought a court order from the ONSC declaring Dr. Bokhari to be a vexatious litigant.

February 4, 2025: the Company announced that it completed a double-blind, randomized, placebo-controlled crossover design clinical trial (NCT06505239) of unbuzzd™. For more information about unbuzzd™ Clinical Trials, please see the Company’s Annual Report on Form 20-F, “*Item 4B. – Business Overview – (i) unbuzzd™ Retail Product Treatment for Alcohol Misuse*” filed with the SEC on March 28, 2025.

February 6, 2025: Unbuzzd Wellness entered into a letter of engagement with a leading New York investment bank to raise up to US\$10,000,000 in capital and explore an initial public offering on a major US public exchange.

February 7, 2025: the Company and Empire Market Ventures, LLC (“Empire”) entered into an investor relations services agreement (the “Empire Agreement”). Pursuant to the Empire Agreement, Empire was engaged for a period of three months. The Company paid Empire US\$25,000 in fees. Empire will be providing the Company with investor awareness and marketing services, which includes giving the Company access to an exclusive Nasdaq, TSX, and ASX mailing list and investor contacts, content creation, media appearances, branding and consulting, and other services aimed at increasing the Company’s engagement with investors.

February 18, 2025: the Company purchased an additional US\$1,000,000 worth of Bitcoin and other cryptocurrencies as part of its strategic efforts.

March 6, 2025: the Company closed the fourth tranche of the December 2024 Offering and issued 100 January 2025 Debenture Units for aggregate gross process of C\$100,000. On March 25, 2025, the investor converted this Debenture into an aggregate of 25,257 Class B Subordinate Voting Shares. In addition, the Company announced it may complete additional tranches of the December 2024 Offering, adjusting each convertible debenture units (each, a “March 2025 Debenture Unit”) to include 76 warrants, with an increased conversion price of C\$6.60 (the “March 2025 Debenture”) and an increased exercise price per warrant of C\$7.00 (the “January 2025 Warrants”). In addition, the March 2025 Debenture removed the VWAP Default, the Prepayment Penalty and the Conversion Bonus.

March 7, 2025: the Company cancelled an aggregate of 7,692 warrants to purchase Class B Subordinate Voting Shares which were previously granted to Mr. Zapolin. The Company and Mr. Zapolin entered into a warrant cancellation agreement, pursuant

to which Mr. Zapolin agreed to cancel the warrants. Management had reviewed Mr. Zapolin's outstanding warrants and determined that the warrants granted to Mr. Zapolin under the Equity Incentive Plan no longer represented a realistic incentive to motivate Mr. Zapolin. Concurrently, the Company granted an aggregate of 7,692 Options to Mr. Zapolin to acquire Class B Subordinate Voting Shares (each, a "Zapolin Option") pursuant to the Equity Incentive Plan, with an exercise price of C\$6.60 per Class B Subordinate Voting Share. Each Zapolin Option granted vested immediately, and the expiry date of the Zapolin Options are on March 7, 2027. If Mr. Zapolin ceases to be a participant under the Equity Incentive Plan for any reason, the expiry date of the Zapolin Options shall be 90 days following the date Mr. Zapolin ceases to be a participant under the Equity Incentive Plan.

March 20, 2025: The Company increased its cryptocurrency holdings with the purchase of an additional US\$1,500,000 worth of Bitcoin and other cryptocurrencies.

March 26, 2025: Unbuzzd Wellness released unbuzzd™ "On-the-Go Powder Stick Packs" in an 8-pack display box, facilitating the sale of unbuzzd™ in convenience, liquor, and drug stores across the United States. The 8-pack display box is available for direct sale to consumers on both amazon.com and unbuzzd.com.

March 26, 2025: the Company retained the services of LWM to enhance its market awareness. This engagement is for a period of 45 days, for \$55,000. As of the date of this report, the Company engages with LWM.

March 27, 2025: the Company appointed Terry Lynch to the Board to replace Dr. Sanjiv Chopra.

March 31, 2025: the Company announced that it has closed the final tranche ("Final Tranche") of the offering announced on December 5, 2024 (the "December 5 NR") as amended on January 20, 2025, and based on the better terms announced on March 7, 2025 (the "March 7 NR"). The Company issued 2,420 Debenture Units (as defined in the December 5 NR, as amended by the March 7 NR) for C\$2,420,000 as part of this Final Tranche bringing the total amount raised to C\$5 million.

March 31, 2025: the Company entered into a joint clinical study with Massachusetts General Hospital (MGH) scientists to validate a novel positron emission tomography (PET) imaging technique to monitor myelin integrity and demyelination in people with multiple sclerosis (MS).

April 3, 2025 – Unbuzzd Wellness launched unbuzzd in Puerto Rico with distribution partner FUSION Distribution Group, a leading distributor of health-conscious food and beverage offerings across Puerto Rico, the Caribbean, and parts of Central and South America.

April 10, 2025 – Unbuzzd Wellness has secured a landmark partnership with the Asian American Trade Associations Council ("AATAC") to expand the retail availability of unbuzzd™, increase sales, and recruit new customers. This partnership will focus on unbuzzd™'s convenient "On-the-Go Powder Stick Packs" which have been scientifically proven to accelerate the reduction of blood alcohol levels and restore mental alertness.

April 14, 2025: the Company announced that the reconsideration motion by Dr. Raza Bokhari at the Court of Appeal for Ontario was dismissed entirely in favour of Quantum BioPharma. As previously disclosed in Quantum BioPharma's news releases issued May 11, 2023, October 4, 2023, and February 5, 2024, and January 17, 2025, Arbitrator Cunningham dismissed Dr. Bokhari's claim that the Company had wrongfully dismissed him, awarding the Company approximately CDN\$2.81 million in costs of the arbitration plus interest. Also, \$175,000 in costs were awarded by Justice Conway in respect of the set aside application, and \$5,000 in costs were awarded by the Court of Appeal totaling \$180,000 in respect of Dr. Raza Bokhari's failed motion for leave to appeal. Dr. Raza Bokhari filed a re-consideration motion with the Court of Appeal for Ontario which is now dismissed entirely and \$180,000 in awards is now due.

April 18, 2025: the Company announced the grant of 60,000 restricted share units (each, an "RSU") pursuant to the Company's equity incentive plan, to Malone Wealth Ventures, LLC.

April 18, 2025: The Company announced that the board of directors of the Company authorized and approved the settlement of outstanding debt owed to arm's length parties by issuing Class B Shares at a deemed price of US\$6.75 per Class B Share. The Class B Shares upon issuance will be subject to a four month and one day hold period pursuant to the policies of the CSE and applicable securities laws.

April 22, 2025: the Company announced the appointment of Kevin Malone as an advisor to the Board of Directors.

On April 23, 2025, the Company expanded its portfolio of residential mortgages by issuing one new mortgage loan, with a principal amount of C\$105,000 with a maturity of one year.

May 5, 2025: the Company announced that it had filed an amended complaint, to the original complaint filed on October 21, 2024, in the US District Court for the Southern District of New York, in response to the Motion to Dismiss filed by the defendants on January 31, 2025.

May 12, 2025: the Company announced the completion of dosing in 90-day repeated dose oral toxicity for Lucid-MS.

May 19, 2025: the Company purchased an additional USD\$1,000,000 worth of Bitcoin and expanded its cryptocurrency holdings to a total value of \$4,500,000.

May 20, 2025: the Company announced an agreement signing with a Global Pharmaceutical Contract Research Organization to prepare an application for Lucid-MS.

May 28, 2025: the Company received an ethics committee approval for Phase 2 clinical for the drug product containing ultra-micronized palmitoylethanolamide (PEA) to address the MCAS disease.

May 29, 2025: Unbuzzd retained MNP as auditor for its capital raise and changed its name to "Unbuzzd Wellness Inc." effective May 23, 2025.

May 30, 2025: the Company received \$2,350,000 from settlement with Dr. Raza Bokhari. This settlement concluded all outstanding issues and prevented any future litigation in various courts in Canada. In accordance with the Sports Coat Prepaid Purchase Agreement, the Company paid \$1,420,000 proceeds received from Dr. Bokhari to Sports Coat, representing the full repayment of the principal and the additional return calculated under the Sports Coat agreement.

June 10, 2025: the Company announced that it purchased additional Bitcoin and other cryptocurrencies and expanded its cryptocurrency portfolio to a total value of \$5,000,000.

June 13, 2025: the Company announced the intention to declare special dividend consisting of Contingent Value Rights based on proceeds from a future litigation settlement to be issued on a 1:1 basis to holders of the Company's Class B Subordinate Voting Shares.

June 17, 2025: the Company announced a first person with MS scanned in a joint study with Massachusetts General hospital.

June 18, 2025: the Company entered into a consulting agreement with Malone Wealth Ventures, LLC ("Malone Wealth") to be effective as of April 15, 2025 to provide consulting services and general business services related to naked short-selling, corruption in the brokerage community and other corporate issues. The Company issued 30,000 Class B Subordinate Voting Shares on April 24, 2025, for prior services, and 60,000 RSUs, which vested in two 30,000-share tranches on June 12 and June 18, 2025, based on market capitalization targets.

June 25, 2025: the Company terminated the consulting agreement with Malone Wealth and his services as a Board Advisor.

June 26, 2025: Unbuzzd Wellness announced its intention to complete a \$5,000,000 capital raise through Regulation D506(c) offering.

June 27, 2025: the Company announced a non-brokered private placement offering to issue twelve Class A Multiple Voting Shares at a price of C\$50.00 per Class A Multiple Voting Share for gross proceeds of C\$600.00. It is intended that Xorax and Fortius will purchase all the Class A Multiple Voting Shares, and the Company filed a material change report more than 21 days before the expected closing of the private placement.

July 1, 2025: Malone Wealth was rehired as a Board Advisor on July 1, 2025.

July 2, 2025: the Company issued 31,035 Class B Subordinate Voting Shares upon the cashless exercise of warrants to one investor attached to convertible debentures purchased pursuant to tranches 4 and 5 of the December 2024 Offering.

July 3, 2025: the Company issued 266,096 Class B Subordinate Voting Shares upon the cashless exercise of warrants to one investor attached to convertible debentures purchased pursuant to tranches 1, 2, 3, and 5 of the December 2024 Offering.

July 7, 2025: the Company issued 8,344 Class B Subordinate Voting Shares upon the cashless exercise of warrants to one investor attached to convertible debentures purchased pursuant to tranche 5 of the December 2024 Offering.

July 8, 2025: the Company issued 8,344 Class B Subordinate Voting Shares upon the cashless exercise of warrants to one investor attached to convertible debentures purchased pursuant to tranche 5 of the December 2024 Offering.

July 8, 2025: the Company through its subsidiary, Huge Biopharma Australia Pty Ltd., the submission of its patented candidate breakthrough drug, Lucid-21-302 (Lucid-MS), to the Innovative Licensing and Access Pathway (ILAP) Passport program in the United Kingdom (UK). The ILAP Passport application was submitted for Lucid-21-302 as a new, first-in-class treatment for multiple sclerosis (MS).

July 10, 2025: the Company issued (i) 11,699 and (ii) 17,698 Class B Subordinate Voting Shares upon the cashless exercise of warrants to two investors attached to convertible debentures purchased pursuant to tranche 5 of the December 2024 Offering.

July 10, 2025: the Company renewed an existing residential mortgage in its portfolio, extending its maturity by one year, with a principal amount of C\$925,000.

July 22, 2025: the Company announced (i) the purchase of 2,000 shares of GameStop Corp. (NYSE: GME), and (ii) the completion of debt settlements with an arm's length creditor totaling \$40,000, comprising (a) a June 18, 2025 settlement of \$30,000 satisfied through the issuance of 1,000 Class B Subordinate Voting Shares at C\$41.14 per Class B Subordinate Voting Share, and (b) a July 9, 2025 settlement of \$10,000 satisfied through the issuance of 680 Class B Subordinate Voting Shares at C\$23.85 per Class B Subordinate Voting Share.

July 24, 2025: the Company purchased 38,129 shares of Genius Group Limited (AMEX: GNS).

July 31, 2025: Further to the Company's press release dated June 26, 2025, Unbuzzd Wellness launched its \$5,000,000 capital raise through Regulation D506(c) offering to fund growth and establish a path to a possible initial public offering.

August 1, 2025: the Company issued 3,014 Class B Subordinate Voting Shares upon the cashless exercise of warrants to one investor attached to the convertible debentures purchased pursuant to tranche 5 of the December 2024 Offering.

August 4, 2025: the Company announced that it had filed a legal reply in opposition to a joint motion to dismiss from defendants CIBC and RBC, continuing its lawsuit seeking over \$700 million USD in damages. The Company alleges that these banks and others engaged in stock price manipulation and "spoofing" of its shares between January 2020 and August 2024, artificially depressing the stock price. The case is being pursued on a contingency basis by the law firms Christian Attar and Freedman Normand Friedland LLP, and the Company has stated it is open to an amicable resolution with the involved banks.

August 5, 2025: the Company announced positive results from the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) clinical trial of its experimental multiple sclerosis drug, Lucid-MS, which concluded that the drug was safe and well-tolerated with no identified safety concerns in healthy participants, a critical step that allows the company to advance the clinical development and prepare for future efficacy trials in patients.

August 8, 2025: the Company announced that Positron Emission Tomography (PET) tracer used in a joint study with Massachusetts General Hospital (MGH) scientists shows the ability to capture differences across lesions in multiple sclerosis (MS) patients, which may prove highly useful for monitoring myelin integrity and demyelination in MS.

August 11, 2025: the Company announced through its subsidiary, Huge Biopharma Australia Pty Ltd., that it has signed an agreement with a leading contract development and manufacturing organization (CDMO) to manufacture an oral drug formulation of Lucid-MS. The oral formulation of Lucid-MS will serve as the drug product for the Company's Phase 2 clinical trial, which will test the efficacy on humans of Lucid-MS as a possible treatment for people to gain back mobility lost with multiple sclerosis (MS). To date numerous animal models over the past decade showed Lucid-MS helped those animals regain their ability to walk.

August 11, 2025: the Company announced that further to its press release dated June 27, 2025, the Company will be seeking shareholder approval of its non-brokered private placement of class A multiple voting shares for aggregate gross proceeds of up to \$600 at its upcoming annual general and special meeting being held on September 26, 2025.

On August 21, 2025, the Company announced the following corporate updates:

1) *Debt Settlement*

On August 12, 2025, the board of directors of the Company authorized the settlement of outstanding debt with one creditor in the amount of \$26,812.50 USD by converting the debt into 1,102 Class B Shares (“Creditor Shares”) at a deemed price of \$24.33 USD per Class B Share.

#### *2) Grant of Restricted Stock Units*

On August 15, 2025, the Board authorized and approved the grant of restricted share units (each, an “RSU”) pursuant to the Equity Incentive Plan. The Company granted 800 RSUs each to Peter Stys and Jack Antel. The RSUs granted vest in accordance with the following schedule:

- a. 500 RSUs will vest to each Clinical Advisor when the Company has a filing application with the US FDA or an equivalent regulatory filing in another country for the start of a clinical Phase 2 trial for Lucid MS within 1 year of grant.
- b. 300 RSUs will vest to each Clinical Advisor when the Company receives a no objection letter or an equivalent regulatory approval from the US FDA or other regulatory institution permitting the start of the clinical trial.

#### *3) Statutory Hold Period and Restrictions on Resale*

The Creditor Shares and RSUs (and any Class B Shares issuable upon their settlement) are subject to a statutory hold period of four months and one day pursuant to the policies of the CSE. The RSUs and Creditor Shares were not registered under the U.S. Securities Act and are not permitted to be offered or sold within the United States absent such registration or an applicable exemption from the registration requirements therein.

#### *4) Change to Advisory Board*

Effective August 15, 2025, the Company terminated the Board Advisor Agreement dated July 1, 2025, with Kevin Malone, and as a result, Mr. Malone ceased serving as an Advisor to the Company’s Board of Directors.

September 10, 2025: the Company announced that Kingswood Capital Partners has initiated coverage of Quantum BioPharma with a BUY rating and a discounted cash flow-based US\$45 price target, assuming successful Phase 2 and 3 trials of Lucid-MS in the 2026-2028 timeframe, and a commercial launch in 2029. The lead analyst of this report is Karen Sterling, PhD, CFA, Senior Equity Analyst at Kingswood Capital Partners. This coverage is unpaid, and Quantum BioPharma provided no consideration for this report.

September 18, 2025: the Company announced that Health Canada has granted a Product License (PN 80144141) for its natural health product, Qlarity. Quantum licensed a similar product, sold as a dietary supplement in the United States under the brand name “unbuzzd” (unbuzzd.com). This Product License from Health Canada permits Quantum to sell Qlarity in Canada. Health Canada’s product license permits the following recommended uses of Qlarity, among others: helps in energy production and metabolism; helps to maintain/support normal electrolyte balance; helps (temporarily) to enhance (physical) energy and motor performance, reduce fatigue, promote endurance, promote mental alertness, and enhance cognitive performance.

On September 26, 2025, the Company announced the following corporate updates:

#### *1) Grant of Restricted Stock Units*

The Company’s board of directors authorized and approved the grant of restricted share units (each, an “RSU”) pursuant to the Company’s omnibus equity incentive plan (“Equity Incentive Plan”). The Company granted 32,000 RSUs to each of Zeeshan Saeed, Anthony Durkacz, and Donal Carroll. The RSUs granted vest upon the compilation of data that would enable the drafting of a Phase 2 MS Study.

#### *2) Stock Options Grant*

In addition, the Company granted 98,000 options (the "Options") to acquire Class B subordinate voting shares in the capital of the Corporation at C\$24.50 per Class B Share, pursuant to the Equity Incentive Plan, to certain directors, officers, employees, and consultants (the "Option Grant"). The Options granted vested immediately and expire on September 24, 2030.

### 3) *Statutory Hold Period and Restrictions on Resale*

The Options and RSUs (and any Class B Shares issuable upon their settlement or exercise) are subject to a statutory hold period of four months and one day, and were not registered under the U.S. Securities Act and are not permitted to be offered or sold within the United States absent such registration or an applicable exemption from the registration requirements therein.

### 4) *Related Party Transaction*

The RSU Grant and the Option Grant, as they relate to the directors of the Company, constitutes a "related party transaction", as such term is defined in Multilateral Instrument 61-101 - Protection of Minority Shareholders in Special Transactions ("MI 61-101") due to the grants to the directors, who are members of the Board, and would require the Company to receive minority shareholder approval for, and obtain a formal valuation for the subject matter of, the transaction in accordance with MI 61-101, prior to the completion of the RSU Grant and the Option Grant, as they relate to the directors of the Company. In its consideration and approval of the RSU Grant and the Option Grant, as they relate to the directors of the Company, the Board determined that the RSU Grant and the Option Grant, as they relate to the directors of the Company, were exempt from the formal valuation and minority approval requirements of MI 61-101. The Company has relied on exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in respectively, sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related party participation in the RSU Grant and the Option Grant, as they relate to the directors of the Company, as neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it involved the related parties, exceeded 25% of the Company's market capitalization (as determined under MI 61-101).

The Company did not file a material change report more than 21 days before the RSU Grant and the Option Grant, as they relate to the directors of the Company, because the details of the grants to related parties to the Company were not settled until shortly prior to the grants. The Company wished to proceed on an expedited basis for business reasons.

October 1, 2025: the Company welcomed Dr. Jack Antel as new clinical advisor to its multiple sclerosis (MS) program centered around Lucid-21-302 ("Lucid-MS"), a patented, new chemical entity investigational drug designed to inhibit demyelination in MS. Dr. Antel will be advising Quantum Biopharma on the clinical development of Lucid-MS including design of efficacy trials of Lucid-MS in people with MS.

October 2, 2025: the Company announced it has received two key final reports related to its potential breakthrough drug for Multiple Sclerosis: the 90-day oral toxicity study report and the toxicokinetic study report for Lucid-MS. These studies were commissioned to provide key data to support an Investigational New Drug (IND) application with the US FDA for a phase-2 clinical trial in Multiple Sclerosis.

October 3, 2025: the Company announced that its Board of Directors set October 27, 2025, as the record date for distributing special dividend Contingent Value Rights (CVRs) to its Class B shareholders on a one-for-one basis, which would entitle holders to a pro rata portion of 10% to 50% of the net proceeds from the Company's ongoing litigation seeking over \$700 million in damages from CIBC, RBC, and others for alleged stock manipulation, with payment only occurring if and when the Company receives net proceeds from a settlement or final judgment.

October 8, 2025: the Company announced a public whistleblower policy offering a cash reward of up to USD \$7 million to any individual or entity that provides definitive and verifiable proof of market manipulation in the Company's stock, with the reward payable only if the information significantly contributes to a trial victory or settlement in its ongoing lawsuit seeking over \$700 million in damages from CIBC, RBC, and other financial institutions for alleged spoofing and stock manipulation.

October 14, 2025: the Company issued a formal response strongly refuting what it characterized as vague, unsubstantiated, and misleading allegations by The Schall Law Firm and DJS Law Group, which had announced an investigation into potential securities law violations, stating that the claims lacked any factual basis or concrete details and appeared to be an opportunistic attempt to damage the Company's reputation and provoke shareholder concern.

October 20, 2025: the Company announced the expiration at 5pm EST of 53,147 warrants (originally 3,454,543 warrants issued pre-reverse stock split (65 to 1)). All warrants were issued to hedge funds and investment funds as part of a previous financing completed on October 20, 2020.

October 29, 2025: the Company announced a non-brokered private placement of up to 30 class A Multiple Voting Shares of the company at the price of C\$25 per class A multiple voting share for aggregate gross proceeds of up to C\$750.

October 31, 2025, the Company filed a prospectus supplement to its effective shelf registration statement, pursuant to which it may from time to time offer and sell up to \$21,225,000 of its Class B Subordinate Voting Shares through an at-the-market offering program.

December 9, 2025: During the year ended December 31, 2025, the portfolio of loan receivables held through FSD Strategic Investments, were sold to a corporation owned by the CFO of the Company. As of December 31, 2025, the Company no longer holds any loans secured by residential properties.

December 10, 2025: the Company announced, further to its October 29, 2025, announcement, that it successfully closed a non-brokered private placement and issued 30 Class A Multiple Voting Shares of the Company at a price of C\$25 per Class A Multiple Voting Share for gross proceeds of C\$750.

December 22, 2025: the Company announced that pursuant to the entry into the at-the-market offering agreement with Rodman and Renshaw LLC ("Rodman") on December 22 2025, the Company, at its description may offer and sell from time to time, through Rodman as sales agent, Class B Subordinate Voting Shares in the capital of the Company having an aggregate offering price of up to \$17,243,174.

December 22, 2025: Paul Durkacz, a shareholder of the Company, filed a class action lawsuit alleging that investors in the Company were the victims of stock manipulation. The lawsuit alleges that between January 6, 2021, and October 15, 2025, shareholders who sold securities of the Company, formerly known as FSD Pharma Inc., were significantly and materially harmed.

December 23, 2025: the Company announced that oral dosing of Lucid-MS was complete in both a 180-day toxicity and toxicokinetic studies. These studies will support the Investigational New Drug (IND) with the US FDA, including the design of a Phase 2 trial of Lucid-MS in people with multiple sclerosis.

March 11, 2026: the Company announced that it intends to complete a non-brokered private placement offering of up to 4,000 convertible debenture units of the Company at a price of \$1,000 per debenture unit. Each debenture unit will consist of (i) one secured convertible debenture having a face value of \$1,000.00; and (ii) 333.33 common share purchase warrants exercisable for 333.33 Class B Subordinate Voting Shares. The debentures will mature on the date that is 24 months from the date of issuance and shall bear interest at a rate of 1.25% per month, beginning on the date of issuance and payable in cash on the last day of each calendar quarter, starting June 30, 2026. The principal sum of the debentures, or any portion thereof, and any accrued but unpaid interest, may be converted into Class B Subordinate Voting Shares at a conversion price of \$3.00 per Class B Subordinate Voting Share. Each warrant shall entitle the holder to acquire one additional Class B Subordinate Voting Shares at a price of \$3.75 per warrant share, for a period of five (5) years from the date of issuance. The Company will use the proceeds from the offering for the ongoing development of the Company's business model and for general working capital purposes. Additionally, the Company intends to settle certain amounts owing to arm's length creditors and insiders of the Company, through the issuance of Class B Subordinate Voting Shares at a deemed price per Class B Subordinate Voting Share equal to the conversion price.

Subsequent to December 31, 2025, the Company successfully sold an aggregate of \$5,350,781 in proceeds under its at-the-market offering agreement with Rodman and Renshaw LLC, as sales agent.

March 11, 2026: the Company issued 44,415 Class B Subordinate Voting Shares to executives and employees of the Company upon the exercise of RSUs.

March 20, 2026: the Company announced that it had closed its first tranche of a private placement offering, initially announced on March 10 and 11, 2026, and issued 3,750 debenture units for aggregate gross proceeds of C\$3,750,000. One director of the Company participated in the private placement offering and subscribed for 300 debenture units, representing aggregate gross proceeds of C\$300,000.

March 20, 2026: the Company also announced the completion of debt settlements by issuing an aggregate of 370,457 Class B Subordinate Voting Shares in the Company to settle approximately C\$1,117,727 of debt owed to certain arm's length creditors and insiders of the Company.

## LEGAL PROCEEDINGS

The Company is engaged in certain legal proceedings, as further described below. Litigation has been, and is expected to be, costly and time-consuming and could divert the attention of management and key personnel from our business operations. Although we intend to vigorously defend ourselves against any pending claims, and future claims that may occur, we cannot assure that we will succeed in defending any of these claims and that the judgments will not be upheld against us. If we are unsuccessful in our defense of these claims or unable to settle the claims in a manner satisfactory to us, we may be faced with outcomes that could have a material adverse effect on the Company and its financial condition. Except as otherwise disclosed below, there are no material outstanding legal proceedings or regulatory actions to which the Company is party, nor, to Company's knowledge, are there any such proceedings or actions contemplated.

### *GBB Drink Lab Litigation*

On May 12, 2023, the Company announced that it had received a lawsuit filed in S.D. Fla. by GBB against the Company, alleging breach of a mutual non-disclosure agreement and misappropriation of trade secrets. GBB claimed that its assets were valued at US\$53,047,000 as of August 30, 2022 (prior to the misappropriation and material breach).

On June 23, 2023, the Company filed a motion to dismiss the complaint. On July 3, 2023, GBB responded in opposition to the Company's motion to dismiss the complaint. On August 24, 2023, the parties filed a proposed joint scheduling report with the S.D. Fla., which set forth various deadlines that would govern this action. Under the proposed joint schedule, the case was supposed to be trial-ready by November 30, 2024. On January 8, 2024, the S.D. Fla. denied the Company's request to dismiss the lawsuit.

On January 22, 2024, the Company filed a third-party complaint against Joseph Romano (a former director of the Company) and a counterclaim against GBB. The Company alleged that Mr. Romano breached his fiduciary duty by providing or fabricating confidential information to GBB, and that GBB aided and abetted this breach. On October 9, 2024, Judge Melissa Damian denied Mr. Romano's motion to dismiss, finding that the Company plausibly alleged Romano breached fiduciary duties, including his duties of loyalty, confidentiality, and to act in the company's best interests. GBB and Romano then denied the allegations in their respective answers.

Discovery concluded in July 2025, and on July 21, 2025, the parties filed various pre-trial motions, including summary judgment motions. On October 9, 2025, the Court granted the motion for the Company's current counsel, Given Pursley LLP, to appear, officially appointing them and relieving prior counsel, Blank Rome LLP. A status conference was held on December 16, 2025, where the Court ruled on several pending motions. The Court granted Mr. Romano's motion for summary judgment, dismissing all claims against him. The Court reserved ruling on the Company's motion for summary judgment, ordering supplemental briefing on the issue of whether GBB has standing to pursue its claims after selling its assets to a third party. The trial, previously set for January 2026, has been continued.

The parties filed supplemental briefs addressing standing in accord with the Court's order. But GBB then filed a reply brief. On February 17, 2026, the Company filed a motion to strike GBB's reply brief and accompanying exhibits, arguing that the filing was unauthorized. On February 18, 2026, GBB filed a response in opposition to the motion to strike. And, as of the date of this annual report, the Court has not yet ruled on standing or the Company's pending summary judgment motion.

### *Raza Bokhari*

On May 21, 2025, the Company entered into a comprehensive settlement agreement with Dr. Raza Bokhari, its former CEO, resolving all outstanding litigation in Canada and the U.S. This concludes disputes originating from Dr. Bokhari's 2021 termination and subsequent legal actions, including:

- A wrongful dismissal arbitration (initially claiming \$30.2 million), dismissed in 2022 with costs awarded to the Company.
- Multiple court proceedings related to share cancellations, indemnification claims, and U.S. enforcement of arbitration awards.

Quantum received a one-time payment of \$2,350,000, recorded as other income during the second quarter of 2025. All outstanding cost awards and claims were mutually waived.

This settlement eliminated all future legal uncertainties and associated costs as announced in the Company's May 30, 2025 press release, which confirmed a \$2.35 million payment from Dr. Bokhari to fully resolve all outstanding claims in Canada and the United States.

#### *Deferred Income*

On December 24, 2024, the Company entered into a Prepaid Forward Purchase Agreement (the "Purchase Agreement") with Sports Coat LLC ("Buyer"). Under the terms of the agreement, the Buyer agreed to provide financing of US\$1,000,000 to the Company in exchange for the right to receive a portion of the proceeds from certain ongoing litigations.

These litigations include, but are not limited to, claims relating to either:

- Alleged market manipulation involving FSD Pharma Inc., Quantum BioPharma Ltd., or any other related entity; or
- Matters involving Dr. Raza Bokhari.

The financing provided under the Purchase Agreement is non-recourse, which stipulates that the Company is not obligated to repay the \$1,000,000 if no proceeds are realized from the litigations. The Buyer assumes the risk of loss in the event of non-collection of litigation proceeds. The agreement does not include a predefined repayment schedule, a specified due date, or a general pledge of the Company's assets as collateral for repayment.

The Purchase Agreement specifies events of default, including failure to pay amounts due, breach of material terms, termination of legal representation without cause, misrepresentation, misappropriation of litigation proceeds, insolvency, or challenges to the agreement's validity. In such cases, the Buyer may declare the full amount immediately due and enforce its security interest.

The Company received the full \$1,000,000, which has been recorded as deferred income as at December 31, 2024.

During the year ended December 31, 2025, the Company received \$2,350,000 in litigation proceeds as part of a settlement related to the Raza Bokhari Claims. In accordance with the agreement with the Buyer, the Company paid \$1,420,000 to the Buyer, representing the full repayment of the principal and the additional return calculated under the Purchase Agreement. The \$1,000,000 initially recorded as deferred income was recognized as other income during the year ended December 31, 2025. The remaining settlement proceeds of \$930,000 were also recognized as other income.

#### *Lawsuit against CIBC World Markets, RBC Dominion Securities, and John Does 1-10*

On October 20, 2024, the Company filed a complaint in the U.S. District Court for the Southern District of New York against CIBC World Markets, Inc., RBC Dominion Securities Inc., and John Does 1-10. The complaint alleges market manipulation through spoofing activities between January 1, 2020, and August 15, 2024. The Company is seeking damages of more than US\$700 million. On May 1, 2025, the Company filed an amended complaint, in response to the Motion to Dismiss filed by the banks on January 31, 2025.

The complaint alleges that between January 1, 2020, and August 15, 2024, the defendants engaged in "spoofing," an unlawful trading practice, to manipulate the market price of Quantum's shares. The complaint details that the defendants placed thousands of spoofing orders to sell, creating the illusion that Quantum's share price was declining. This practice allegedly "tricked" other investors into selling their shares at lower prices, driving the Company's share price downward. The defendants then purchased shares at artificially depressed prices, positioning themselves to profit when the market price rebounded. The Company claims to have suffered significant damage and seeks to recover more than USD 700 million. It alleges that it sold approximately 90 million shares of its stock on U.S. and Canadian exchanges during the relevant period at artificially depressed prices due to the defendants' spoofing activities. The complaint names CIBC World Markets, Inc., RBC Dominion Securities Inc., and John Does 1 through 10 as defendants. It asserts three claims for relief: violation of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5(a) and (c), violation of Section 9(a)(2) of the Securities Exchange Act of 1934, and New York Common Law Fraud.

The defendants filed a motion to dismiss on June 16, 2025, and the Company is awaiting the decision from U.S. district Court for the Southern District of New York.

## **Additional Regulatory Matters**

In response to OSC inquiries regarding our securities trading activity, the Company has maintained an active investigation into potential market irregularities. We provide historical context regarding this ongoing matter, which is an important aspect of our regulatory compliance efforts.

### *Quantum Response to OSC Inquiry*

On August 11, 2023, external legal counsel sent a letter to the Ontario Securities Commission ("OSC"). This letter was in response to a comment letter from the OSC regarding the Company's Preliminary Short Form Base Shelf Prospectus filed on July 11, 2023. The letter addressed inquiries from the OSC about the Company's investigation into possible naked short selling and market manipulation of the Company's securities.

Key points of the letter:

- The Company's external counsel and Christian Attar (collectively referred to as "Law Firms") were jointly representing Quantum in the matter concerning possible naked short selling and market manipulation of the Company's securities.
- Quantum had first suspected share price manipulation in 2021 when it discovered imbalances between reported shares held by brokers and authorized shares on deposit in both Canadian and U.S. exchanges.
- The Board of Directors discussed naked short selling and market manipulation in a meeting on June 29, 2023, and decided to retain Christian Attar.
- Other than an information package submitted to the OSC on June 23, 2023, Quantum had not been in contact with other regulatory bodies regarding this matter.
- The investigation was ongoing at the time, with the Law Firms reviewing documents, trading data, and interviewing witnesses.
- The Company has an Insider Trading and Blackout Period policy, but the disclosure of the possible naked short selling and market manipulation did not trigger a blackout period.
- The letter emphasized the preliminary nature of the investigation and its ongoing status. It stated that it was premature to identify any parties or individuals who might be implicated in the matter. Furthermore, the Law Firms were unable to provide an accurate timeline for the completion of their investigations at that point.
- The letter also noted that any decision regarding potential litigation against third parties would depend on the investigation's findings and could not be determined until the inquiry was concluded.

## SELECTED FINANCIAL HIGHLIGHTS

The following table presents selected financial information for the three months and years ended December 31, 2025, and 2024:

	Three months ended December 31,		Years ended December 31,	
	2025	2024	2025	2024
	\$	\$	\$	\$
<b>Expenses</b>				
General and administrative	1,365,158	1,930,572	9,047,918	9,410,097
External research and development fees	70,404	4,280,330	2,763,174	6,083,378
Share-based payments	808,452	(82,477)	2,945,502	152,214
Depreciation and amortization	129,371	112,803	545,780	490,571
<b>Total operating expenses</b>	<b>2,373,385</b>	<b>6,241,228</b>	<b>15,302,374</b>	<b>16,136,260</b>
<b>Loss from operations</b>	<b>(2,373,385)</b>	<b>(6,241,228)</b>	<b>(15,302,374)</b>	<b>(16,136,260)</b>
<b>Net loss from operations</b>	<b>(3,703,032)</b>	<b>(5,456,278)</b>	<b>(26,956,840)</b>	<b>(14,915,529)</b>

The following table presents selected financial information for the three months and years ended December 31, 2024, and 2023:

	Three months ended December 31,		Years ended December 31,	
	2024	2023	2024	2023
	\$	\$	\$	\$
<b>Expenses</b>				
General and administrative	1,930,572	1,373,300	9,410,097	9,032,724
External research and development fees	4,280,330	(29,961)	6,083,378	3,859,178
Share-based payments	(82,477)	99,384	152,214	3,835,475
Depreciation and amortization	112,803	122,217	490,571	2,506,316
Impairment loss	—	236,186	—	4,555,805
<b>Total operating expenses</b>	<b>6,241,228</b>	<b>1,801,126</b>	<b>16,136,260</b>	<b>23,789,498</b>
<b>Loss from operations</b>	<b>(6,241,228)</b>	<b>(1,651,566)</b>	<b>(16,136,260)</b>	<b>(18,230,588)</b>
<b>Net loss from operations</b>	<b>(5,456,278)</b>	<b>(1,651,566)</b>	<b>(14,915,529)</b>	<b>(18,230,588)</b>

## REVIEW OF OPERATIONS 2025

The following table outlines our consolidated statements of loss for the three months and years ended December 31, 2025, and 2024:

	For the three months ended December 31,		Change \$	Change %
	2025	2024		
	\$	\$		
<b>Expenses</b>				
General and administrative	1,365,158	1,930,572	(565,414)	-29%
External research and development fees	70,404	4,280,330	(4,209,926)	-98%
Share-based payments	808,452	(82,477)	890,929	-1080%
Depreciation and amortization	129,371	112,803	16,568	15%
<b>Total operating expenses</b>	<b>2,373,385</b>	<b>6,241,228</b>	<b>(3,867,843)</b>	<b>-62%</b>
<b>Loss from operations</b>	<b>(2,373,385)</b>	<b>(6,241,228)</b>	<b>3,867,843</b>	<b>-62%</b>
Interest income	22,285	(132,075)	154,360	-117%
Other income	2,727	(3,989)	6,716	-168%
Finance expense, net	(72,637)	1,875	(74,512)	-3974%
Accretion and interest expense	13	14,560	(14,547)	-100%
Gain on settlement of debt	42,777	(737,573)	780,350	-106%
Change in fair value of derivative liabilities and warrant liability	(1,834)	(73,220)	71,386	-97%
Unrealized loss on change in fair value of digital assets	1,603,235	141,770	1,461,465	1031%
Realized (gain) on sale of digital assets	(103,785)	—	(103,785)	100%
Change in fair value of investments	(105,076)	3,702	(108,778)	-2938%
Realized loss on sale of investments	(175,194)	—	(175,194)	100%
Realized loss on sale of finance receivables	117,136	—	117,136	100%
<b>Net loss from operations</b>	<b>(3,703,032)</b>	<b>(5,456,278)</b>	<b>1,753,246</b>	<b>-32%</b>
<b>Other comprehensive loss</b>				
Items that may be subsequently reclassified to loss:				
Exchange gain (loss) on translation of foreign operations	(184,613)	(782,266)	597,653	-76%
<b>Comprehensive loss</b>	<b>(3,887,645)</b>	<b>(6,238,544)</b>	<b>2,350,899</b>	<b>-38%</b>

	For the years ended December 31,		Change \$	Change %
	2025	2024		
	\$	\$		
<b>Expenses</b>				
General and administrative	9,047,918	9,410,097	(362,179)	-4%
External research and development fees	2,763,174	6,083,378	(3,320,204)	-55%
Share-based payments	2,945,502	152,214	2,793,288	1835%
Depreciation and amortization	545,780	490,571	55,209	11%
<b>Total operating expenses</b>	<b>15,302,374</b>	<b>16,136,260</b>	<b>(833,886)</b>	<b>-5%</b>
<b>Loss from operations</b>	<b>(15,302,374)</b>	<b>(16,136,260)</b>	<b>833,886</b>	<b>-5%</b>
Interest income	(236,084)	(572,891)	336,807	-59%
Other income	(1,946,491)	(3,989)	(1,942,502)	48696%
Finance expense, net	158,063	33,017	125,046	379%
Accretion and interest expense	460,577	14,560	446,017	3063%
Gain on settlement of debt	(43,336)	(732,417)	689,081	-94%
Change in fair value of derivative liabilities and warrant liability	11,909,532	(104,483)	12,014,015	-11499%
Unrealized loss on change in fair value of digital assets	771,863	141,770	630,093	444%
Realized (gain) on sale of digital assets	(593,922)	-	(593,922)	100%
Change in fair value of investments	(257,956)	3,702	(261,658)	-7068%
Realized loss on sale of investments	(175,194)	-	(175,194)	100%
Realized loss on sale of finance receivables	117,136	-	117,136	100%
Loss on issuance of convertible debt	1,490,278	-	1,490,278	100%
<b>Net loss from operations</b>	<b>(26,956,840)</b>	<b>(14,915,529)</b>	<b>(12,041,311)</b>	<b>81%</b>

**Other comprehensive loss**

Items that may be subsequently reclassified to loss:

Exchange gain (loss) on translation of foreign operations	<b>40,738</b>	(366,546)	407,284	-111%
<b>Comprehensive loss</b>	<b>(26,916,102)</b>	(15,282,075)	(11,634,027)	76%

**REVIEW OF OPERATIONS FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2025, AND 2024***General and administrative*

General and administrative expenses for the three months and years ended December 31, 2025, and 2024 are comprised of:

	For the three months ended December 31,				For the years ended December 31.			
	2025	2024	Change	Change	2025	2024	Change	Change
	\$	\$	\$	%	\$	\$	\$	%
Professional fees	<b>584,497</b>	638,424	(53,927)	-8%	<b>3,278,735</b>	3,074,130	204,605	7%
Investor relations	<b>209,888</b>	371,699	(161,811)	-44%	<b>1,896,573</b>	1,748,242	148,331	8%
Salaries, wages and benefits	<b>209,354</b>	432,408	(223,054)	-52%	<b>2,204,319</b>	2,658,364	(454,045)	-17%
Consulting fees	<b>356,876</b>	93,084	263,792	283%	<b>793,753</b>	797,863	(4,110)	-1%
Office and general administrative	<b>(9,041)</b>	240,541	(249,582)	-104%	<b>889,573</b>	879,272	10,301	1%
Foreign exchange loss (gain)	<b>13,584</b>	154,416	(140,832)	-91%	<b>(15,035)</b>	252,226	(267,261)	-106%
	<b>1,365,158</b>	1,930,572	(565,414)	-29%	<b>9,047,918</b>	9,410,097	(362,179)	-4%

*Professional fees*

Professional fees decreased from \$638,424 to \$584,497 or 8% and increased from \$3,074,130 to \$3,278,735 or 7% for the three months and year ended December 31, 2025, respectively, compared to the equivalent periods in the prior year. The annual increase was attributable to a 13% increase in legal fees and a 14% increase in audit fees incurred during the year. The increase in cost was attributable to the greater complexity of the Company's transactions during FY2025.

*Investor relations*

Investor relations costs decreased from \$371,699 to \$209,888 or 44% and increased from \$1,748,242 to \$1,896,573 or 8% for the three months and year ended December 31, 2025, respectively, compared to the equivalent periods in the prior year. The Company experienced heightened advertising and promotional costs for its capital raise cycle.

*Salaries, wages and benefits*

Salaries, wages, and benefits expenses decreased from \$432,408 to \$209,354 or 52% and decreased from \$2,658,364 to \$2,204,319, or 17% for the three months and year ended December 31, 2025, respectively, compared to the equivalent periods in the prior year. The decrease year over year was primarily attributable to decreased bonus expenses recorded of 35%.

*Consulting fees*

Consulting fees increased from \$93,084 to \$356,876 or 283% and decreased from \$797,863 to \$793,753 or 1% for the three months and year ended December 31, 2025, respectively, compared to the equivalent periods in the prior year. The Company maintained the same level of cost related to consulting fees during 2025 and 2024.

*General office, insurance, and administration expenditures*

General office, insurance, and administration expenditures for the three months and years ended December 31, 2025, and 2024 are comprised of the following:

	For the three months ended December 31,				For the years ended December 31.			
	2025	2024	Change	Change	2025	2024	Change	Change
	\$	\$	\$	%	\$	\$	\$	%
Insurance, shareholders and public company costs	<b>7,582</b>	74,240	(66,658)	-90%	<b>324,294</b>	339,103	(14,809)	-4%
Travel, meals and entertainment	<b>55,909</b>	87,614	(31,705)	-36%	<b>287,687</b>	202,403	85,284	42%
Office and general administrative	<b>(72,532)</b>	78,687	(151,219)	-192%	<b>277,592</b>	337,766	(60,174)	-18%
Total	<b>(9,041)</b>	240,541	(249,582)	-104%	<b>889,573</b>	879,272	10,301	1%

#### *Insurance, shareholders, and public company costs*

Insurance, shareholders and public company costs decreased from \$74,240 to \$7,582 or 90% and decreased from \$339,103 to \$324,294 or 4% for the three months and year ended December 31, 2025, respectively, compared to the equivalent periods in the prior year. Expenses mainly consisted of ongoing director insurance premiums, stock exchange listing fees (CSE and NASDAQ), shareholder communication costs, filing fees, and regulatory expenses.

#### *Travel, meals and entertainment*

Travel, meals and entertainment expenses decreased from \$87,614 to \$55,909 or 36% and increased from \$202,403 to \$287,687 or 42% for the three months and year ended December 31, 2025, respectively, compared to the equivalent periods in the prior year. Travel, meals and entertainment expenses fluctuate from period to period based on the nature of the transactions the Company undertakes.

#### *Office and general administrative*

Office and general administrative expenses decreased from \$78,687 to a recovery of \$72,532 or 192% and decreased from \$337,766 to \$277,592 or 18% for the three months and year ended December 31, 2025, respectively, compared to the equivalent periods in the prior year. The recovery during Q42025 was mainly driven by the fact that Unbuzzd received credit against marketing costs, thus lower its aggregate marketing cost for the year.

#### *Foreign exchange loss*

Foreign exchange loss decreased from \$154,416 to \$13,584 or 91% and decreased from a loss of \$252,226 to a gain of \$15,035 or 106% for the three months and year ended December 31, 2025, respectively, compared to the equivalent periods in the prior year. The US dollar depreciated against the Canadian dollar during FY2025 by approximately 8%, benefiting cash holding denominated in Canadian dollar.

#### *External research and development fees*

External research and development expenses decreased from \$4,280,330 to \$70,404 or 98% and decreased from \$6,083,378 to \$2,763,174 or 55% for the three months and year ended December 31, 2025, respectively, compared to the equivalent periods in the prior year. The Company benefited from the R&D tax credit initiatives provided by Australian regulations during FY2025 and thereby reducing its research expenditures by approximately \$1 million and \$870,000, related to Huge Biopharma and FSD Australia, respectively. The FY2025 is the first year where the Company benefited from the R&D tax credits provided by the Australian authorities. The Company reduced its research expenditure related to the FSD201 product to address the mast cell activation syndrome ("MCAS") disease by 67% from \$1,839,062 to \$612,170 during FY2025, which was incurred through FSD Australia. The reduced expenditure resulted from additional time required from the Company's Australian counterparts to organize the process and the development of the phase 2 clinical trial of FSD-201 in MCAS.

#### *Share-based payments*

Share-based payments increased from a reversal of \$82,477 to an expense of \$808,452 or 1,080% and increased from \$152,214 to \$2,945,502 or 1835% for the three months and year ended December 31, 2025, respectively, compared to the equivalent periods in the prior year. Share-based payments expense changes based on the variability in the number of options granted, vesting periods of the options, the number of Performance Share Units ("PSUs") granted, the number of RSUs granted, vesting periods of the PSUs and RSUs, number of warrants granted, vesting periods of the warrants, the grant date fair values of share-based awards, and share-based bonuses issued. During the year ended December 31, 2025, the Company granted stock options and RSUs, which represented a total expense of \$2,901,197. The remainder of the share-based payments expense of \$44,305 related to share-based equity compensation of Unbuzzd during the year ended December 31, 2025.

#### *Depreciation and amortization*

Depreciation and amortization increased from \$112,803 to \$129,371 or 15% and increased from \$490,571 to \$545,780 or 11% for the three months and year ended December 31, 2025, respectively, compared to the equivalent periods in the prior year. The Company's intangible asset for Lucid, representing the license agreement with University Health Network, is the primary driver of approximately 80% of depreciation and amortization expense during the year ended December 31, 2025.

#### *Interest income*

Interest income decreased from \$132,075 to an expense of \$22,285 or 117% and decreased from \$572,891 to \$236,084 or 59% for the three months and year ended December 31, 2025, respectively, compared to the equivalent periods in the prior year. Interest income primarily consisted of interest earned from the residential property investments through the FSD Strategic Investment entity.

#### *Other income*

During the year ended December 31, 2025, the Company received \$2,350,000 in litigation proceeds as part of a settlement related to the Raza Bokhari Claims accordance with the Sports Coat Prepaid Purchase Agreement, the Company paid \$1,420,000 to Sports Coat, representing the full repayment of the principal and the additional return calculated under the agreement. The \$1,000,000 initially recorded as deferred income was recognized as other income during the year ended December 31, 2025. The remaining settlement proceeds of \$930,000 were also recognized as other income.

#### *(Gain) loss on settlement of debt*

During the three months and year ended December 31, 2025, the Company incurred a loss on the settlement of debt of \$42,777 and a gain of \$43,336, respectively, with arm's-length creditors.

During the three months and year ended December 31, 2024, the Company incurred a gain on settlement of debt of \$737,573 and \$732,417, respectively, related to the shares for debt transaction with arms-length creditors.

The Company incurs gains or losses on the settlement of debts, depending on the price of the shares on the date of debt settlement and the prices stated in the agreements.

#### *Loss (gain) on change in fair value of derivative liability*

In August 2020, the Company issued 42,499 Class B Subordinate Voting Shares and 21,249 warrants to purchase Class B Subordinate Voting Shares for total cash proceeds of \$9,999,997. Each warrant is exercisable to purchase one Class B Subordinate Voting Share of the Company at an exercise price of \$276.90 per share and expires five years from the date of issuance.

##### *1) December 2024 Debentures*

During the year ended December 31, 2024, the Company issued 80,000 warrants pursuant to a convertible debenture with derivative liability components. The fair value of these warrants on the date of issuance was \$212,000. The fair value of these warrants increased to a total amount of \$1,797,056 over the first three quarters of 2025, prior to exercise. This increase in fair valuation, driven by share price appreciation, resulted in a non-cash loss on change in fair value of \$1,585,056 for the year ended December 31, 2025 (2024 - \$Nil). All warrants were exercised during the third quarter of 2025. Consequently, the fair value of the warrants was \$Nil as of December 31, 2025 (December 31, 2024 - \$212,000).

The fair value of the conversion feature as at dates of conversion on May 5, 2025 and May 23, 2025, was \$1,088,190, and \$739,260, respectively, resulting in a total non-cash loss on change in fair value of \$1,003,355 for the year ended December 31, 2025 (2024 - \$Nil). Consequently, the fair value of the conversion feature as at December 31, 2025, was \$Nil (December 31, 2024 - \$280,000) as the entire amount of the debenture was converted into Class B Subordinate Voting Shares during the second quarter of 2025.

##### *2) January 2025 Debentures*

On January 20, 2025, the Company issued 152,577 warrants pursuant to a convertible debenture with derivative liability components. The fair value of the warrant liability at the date of issuance on January 20, 2025, was \$405,656. The fair value of these warrants increased to a total amount of \$3,484,401 over the first three quarters of 2025, prior to exercise. This increase in fair valuation, driven by share price appreciation, resulted in a non-cash loss on change in fair value of \$3,078,745 for the year ended December 31, 2025 (2024 - \$Nil). All warrants were subsequently exercised during the year ended December 31, 2025. Consequently, the fair value of the warrants was \$Nil as of December 31, 2025 (December 31, 2024 - \$Nil).

The fair value of the conversion feature as at dates of conversion on February 7 and February 26, 2025, was \$2,912,862, and \$656,513, respectively, resulting in a total non-cash loss on change in fair value of \$1,513,174 for the year ended December 31, 2025 (2024 - \$Nil). Consequently, the fair value of the conversion feature as at December 31, 2025, was \$Nil (December 31, 2024 - \$Nil) as the entire amount of the debenture was converted into Class B Subordinate Voting Shares during the first and second quarter of 2025.

### 3) March 6, 2025 Debentures

On March 6, 2025, the Company issued 10,309 warrants pursuant to the convertible debenture with derivative liability components. The fair value of the warrant liability as at date of issuance on March 6, 2025, was \$38,702. The fair value of these warrants increased to a total amount of \$235,883 over the first three quarters of 2025, prior to exercise. This increase in fair valuation, driven by share price appreciation, resulted in a non-cash loss on change in fair value of \$197,181 for the year ended December 31, 2025 (2024 - \$Nil). All warrants were subsequently exercised during the third quarter of 2025. Consequently, the fair value of the warrants was \$Nil as of December 31, 2025 (December 31, 2024 - \$Nil).

### 4) March 28, 2025 Debentures

On March 28, 2025, the Company issued 183,920 warrants pursuant to the convertible debenture with derivative liability components. The fair value of the warrant liability as at date of issuance on March 28, 2025, was \$1,218,875. The fair value of these warrants increased to a total amount of \$3,565,586 over the first three quarters of 2025, prior to exercise. This increase in fair valuation, driven by share price appreciation, resulted in a non-cash loss on change in fair value of \$2,346,711 for the year ended December 31, 2025 (2024 - \$Nil). All warrants were subsequently exercised during the third quarter of 2025. Consequently, the fair value of the warrants was \$Nil as of December 31, 2025 (December 31, 2024 - \$Nil).

During the year ended December 31, 2025, investors converted partial amounts of into the Company's Class B Subordinate Voting Shares on various dates throughout the second quarter of 2025, resulting in a total non-cash loss on change in fair value of \$2,185,313 for the year ended December 31, 2025 (2024 - \$Nil). Consequently, the fair value of the conversion feature as at December 31, 2025, was \$Nil (December 31, 2024 - \$Nil) as the entire amount of the debenture was converted into Class B Subordinate Voting Shares during the second quarter of 2025.

#### Unrealized loss on change in fair value of digital assets

The Company's investments in digital assets are accounted for at fair value through profit or loss. The Company recognized an unrealized loss on change in fair value of \$1,603,235 and \$771,863, for the three months end year ended December 31, 2025, respectively (2024 - \$141,770 and \$141,770). The unrealized loss recorded during the fourth quarter of 2025 was primarily attributable to the approximate 30% drawdown of Bitcoin, negatively impacting the Company's overall crypto portfolio.

#### Realized gain from sale of digital assets

During the year ended December 31, 2025, the Company invested an additional \$5,632,576 in digital assets. The Company also sold \$1,906,503 in digital assets for total gross proceeds of \$2,500,425 and recognized a gain on sale of digital assets of \$103,785 and \$593,922 for the three months and year ended December 31, 2025, respectively (2024 - \$Nil and \$Nil).

#### Loss on changes in fair value of investments

The Company has various investments accounted for at fair value through profit or loss resulting in recognition of loss or gain as the fair value fluctuates. The following tables outline changes in investments during the year ended December 31, 2025:

Entity	Instrument	Balance at December 31, 2024	Additions	Disposal	Redemptions	Change in fair value through profit or loss	Effects of foreign exchange	Balance at December 31, 2025
		\$	\$	\$	\$	\$	\$	\$
A2ZCryptoCap Inc.	Shares	2,224	-	-	-	1,570	-	3,794
Royal Bank of Canada	GIC	20,850	-	-	-	-	1,039	21,889
Meridian	GIC	1,181,499	-	-	(1,181,499)	-	-	-
Gamestop	Shares	-	48,516	-	-	(8,358)	-	40,158
Genius Group Ltd	Shares	-	49,009	(2,217)	-	(24,886)	-	21,906
JZR Gold	Shares	-	214,161	(283,097)	-	68,936	-	-
JZR Gold	Warrants	-	150,639	-	-	220,694	-	371,333
		1,204,573	462,325	(285,314)	(1,181,499)	257,956	1,039	459,080
							<b>Current</b>	459,080
							<b>Non-current</b>	-

#### Realized gain on sale of investments

The Company recognized a gain of \$175,194 for the three months and year ended December 31, 2025, related to the sale of investments. The investments sold were related to the JZR Gold shares.

### Realized loss on sale of finance receivables

The Company recognized a loss of \$117,136 for the three months and year ended December 31, 2025, related to the sale of finance receivables. During the year ended December 31, 2025, the Company, through its subsidiary FSD Strategic Investments, sold its entire portfolio of loan receivables to a corporation owned by the CFO of the Company.

### Loss on issuance of convertible debt

The Company incurred a loss on issuance of convertible debt of \$1,490,278 for the year ended December 31, 2025, as the fair value of warrants and conversion feature pursuant to the third tranche of the December 2024 debentures issued on January 20, 2025, were higher than the principal debt amount on the date of issuance.

## RESULTS OF OPERATIONS 2024

The following table outlines our consolidated statements of loss for the three months and years ended December 31, 2024, and 2023:

	For the three months ended December 31,		Change	%
	2024	2023		
	\$	\$		
<b>Expenses</b>				
General and administrative	1,930,572	1,373,300	557,272	41%
External research and development fees	4,280,330	(29,961)	4,310,291	-14386%
Share-based payments	(82,477)	99,384	(181,861)	-183%
Depreciation and amortization	112,803	122,217	(9,414)	-8%
Impairment loss	—	236,186	(236,186)	-100%
<b>Total operating expenses</b>	<b>6,241,228</b>	<b>1,801,126</b>	<b>4,440,102</b>	<b>247%</b>
<b>Loss from operations</b>	<b>(6,241,228)</b>	<b>(1,801,126)</b>	<b>(4,440,102)</b>	<b>247%</b>
Interest income	(132,075)	(153,791)	21,716	-14%
Other income	(3,989)	—	(3,989)	-100%
Finance expense, net	1,875	12	1,863	15525%
Gain on settlement of debt	(737,573)	—	(737,573)	100%
Gain on measurement of financial liability	—	—	—	100%
Gain on change in fair value of derivative liabilities and warrant liability	(73,220)	(99,045)	25,825	-26%
Unrealized loss on change in fair value of digital assets	141,770	—	141,770	100%
Loss on changes in fair value of investments	3,702	103,264	(99,562)	-96%
<b>Net loss from operations</b>	<b>(5,456,278)</b>	<b>(1,651,566)</b>	<b>(3,804,712)</b>	<b>230%</b>
<b>Other comprehensive loss</b>				
Items that may be subsequently reclassified to loss:				
Exchange gain (loss) on translation of foreign operations	(782,266)	(285,119)	(497,147)	174%
<b>Comprehensive loss</b>	<b>(6,238,544)</b>	<b>(1,936,685)</b>	<b>(4,301,859)</b>	<b>222%</b>

	For the years ended December 31,		Change	%
	2024	2023		
	\$	\$		
<b>Expenses</b>				
General and administrative	9,410,097	9,032,724	377,373	4%
External research and development fees	6,083,378	3,859,178	2,224,200	58%
Share-based payments	152,214	3,835,475	(3,683,261)	-96%
Depreciation and amortization	490,571	2,506,316	(2,015,745)	-80%
Impairment loss	—	4,555,805	(4,555,805)	-100%
<b>Total operating expenses</b>	<b>16,136,260</b>	<b>23,789,498</b>	<b>(7,653,238)</b>	<b>-32%</b>
<b>Loss from operations</b>	<b>(16,136,260)</b>	<b>(23,789,498)</b>	<b>7,653,238</b>	<b>-32%</b>
Interest income	(572,891)	(786,363)	213,472	-27%
Other income	(3,989)	—	(3,989)	100%
Finance expense, net	33,017	299	32,718	10942%
Gain on settlement of debt	(732,417)	—	(732,417)	100%
Gain on measurement of financial liability	—	(4,939,015)	4,939,015	-100%
Gain on change in fair value of derivative liabilities and warrant liability	(104,483)	(212,256)	107,773	-51%

Unrealized loss on change in fair value of digital assets	141,770	—	141,770	100%
Loss on changes in fair value of investments	3,702	378,425	(374,723)	-99%
<b>Net loss from operations</b>	<b>(14,915,529)</b>	<b>(18,230,588)</b>	<b>3,315,059</b>	<b>-18%</b>
<b>Other comprehensive loss</b>				
Items that may be subsequently reclassified to loss:				
Exchange gain (loss) on translation of foreign operations	(366,546)	(235,260)	(131,286)	56%
<b>Comprehensive loss</b>	<b>(15,282,075)</b>	<b>(18,465,848)</b>	<b>3,183,773</b>	<b>-17%</b>

## REVIEW OF OPERATIONS FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2024, AND 2023

### General and administrative

General and administrative expenses for the three months and years ended December 31, 2024, and 2023 are comprised of:

	For the three months ended December 31,				For the years ended December 31.			
	2024	2023	Change	Change	2024	2023	Change	Change
	\$	\$	\$	%	\$	\$	\$	%
Professional fees	638,424	861,831	(223,407)	-26%	3,074,130	3,248,233	(174,103)	-5%
Investor relations	371,699	70,159	301,540	430%	1,748,242	665,915	1,082,327	163%
Salaries, wages and benefits	432,408	406,905	25,503	6%	2,658,364	1,855,087	803,277	43%
Consulting fees	93,084	232,021	(138,937)	-60%	797,863	1,305,434	(507,571)	-39%
Office and general administrative	240,541	246,912	(6,371)	-3%	879,272	2,294,476	(1,415,204)	-62%
Foreign exchange loss (gain)	154,416	(444,528)	598,944	-135%	252,226	(336,421)	588,647	-175%
	<b>1,930,572</b>	<b>1,373,300</b>	<b>557,272</b>	<b>41%</b>	<b>9,410,097</b>	<b>9,032,724</b>	<b>377,373</b>	<b>4%</b>

### Professional fees

Professional fees decreased from \$861,831 to \$638,424 or 26% and decreased from \$3,248,233 to \$3,074,130 or 5% for the three months and year ended December 31, 2024, respectively, compared to the equivalent periods in the prior year. Professional fees exhibited significant fluctuations throughout the year, driven by substantial legal and audit-related expenditures, with notable peaks in Q1 and Q3 due to large accruals, settlements, and adjustments. The overall trend reflected heightened activity in financial adjustments, particularly in the latter half of the year as settlement were reached with a majority of law firms.

### Investor relations

Insurance, shareholders and public company costs increased from \$70,159 to \$371,699 or 430% and increased from \$665,915 to \$1,748,242 or 163% for the three months and year ended December 31, 2024, respectively, compared to the equivalent periods in the prior year. The significant increase in investor relations and related expenses for the year ended December 31, 2024, was driven by expenditures in media and promotional activities, with a notable concentration of spending in Q2 and Q3. The year also saw a mix of high-value, one-time payments and recurring operational costs, reflecting heightened activity in investor engagement and brand promotion.

### Salaries, wages and benefits

Salaries, wages, and benefits expenses increased from \$406,905 to \$432,408 or 6% and increased from \$1,855,087 to \$2,658,364, or 43% for the three months and year ended December 31, 2024, respectively, compared to the equivalent periods in the prior year. Base compensation amounted to \$1.3M for the year ended December 31, 2024, while an executive bonus of \$997,920 was awarded in August 2024.

### Consulting fees

Consulting fees decreased from \$232,021 to \$93,084 or 60% and decreased from \$1,305,434 to \$797,863 or 39% for the three months and year ended December 31, 2024, respectively, compared to the equivalent periods in the prior year. The consulting fees include historical expenses from a consulting firm no longer engaged by the Company. The Company now maintains

ongoing relationships for specialized consulting needs with a few new firms. Approximately 25% of consulting fees were associated with director fee.

#### *General office, insurance, and administration expenditures*

General office, insurance, and administration expenditures for the three months and years ended December 31, 2024, and 2023 are comprised of the following:

	For the three months ended December 31,				For the years ended December 31,			
	2024	2023	Change	Change	2024	2023	Change	Change
	\$	\$	\$	%	\$	\$	\$	%
Insurance, shareholders and public company costs	<b>74,240</b>	154,751	(80,511)	-52%	<b>339,103</b>	689,187	(350,084)	-51%
Travel, meals and entertainment	<b>87,614</b>	31,968	55,646	174%	<b>202,403</b>	154,124	48,279	31%
Office and general administrative	<b>78,687</b>	60,193	18,494	31%	<b>337,766</b>	1,451,165	(1,113,399)	-77%
Total	<b>240,541</b>	246,912	(6,371)	-3%	<b>879,272</b>	2,294,476	(1,415,204)	-62%

#### *Insurance, shareholders, and public company costs*

Insurance, shareholders and public company costs decreased from \$154,751 to \$74,240 or 52% and decreased from \$689,187 to \$339,103 or 51% for the three months and year ended December 31, 2024, respectively, compared to the equivalent periods in the prior year. Expenses mainly consisted of ongoing D&O insurance premiums, stock exchange listing fees (CSE and NASDAQ), shareholder communication costs, filing fees, and regulatory expenses.

#### *Travel, meals and entertainment*

Travel, meals and entertainment expenses increased from \$31,968 to \$87,614 or 174% and increased from \$154,124 to \$202,403 or 31% for the three months and year ended December 31, 2024, respectively, compared to the equivalent periods in the prior year. Travel, meals and entertainment expenses fluctuate from period to period based on the nature of the transactions the Company undertakes.

#### *Office and general administrative*

Office and general administrative expenses increased from \$60,193 to \$78,687 or 31% and decreased from \$1,451,165 to \$337,766 or 77% for the three months and year ended December 31, 2024, respectively, compared to the equivalent periods in the prior year. This decrease primarily reflects a change in accounting treatment for unbuzzd™ product development costs. In 2023, when unbuzzd™ was in its conceptual phase, approximately \$1.3 million of development costs were recorded as general and administrative expenses, comprising approximately \$877,000 in medical and scientific development costs through the entity Lucid and \$500,000 in commercial viability assessment costs through Quantum. As the product advanced beyond the conceptual phase in 2024, these costs were classified under research and development expenses, resulting in the significant reduction in general and administrative expenses.

#### *Foreign exchange (gain) loss*

Foreign exchange gain decreased from \$444,528 to a foreign exchange loss of \$154,416 or -135% and from a gain of \$336,421 to a loss of \$252,226 or -175% for the three months and year ended December 31, 2024, respectively, compared to the equivalent periods in the prior year. The primary reason for the change in foreign exchange was the change in the Canadian dollar relative to the US dollar and its impact on financial instruments denominated in the Canadian dollar. The strong appreciation of the US dollar versus the Canadian dollar in 2024 negatively impacted returns on the Company's Canadian dollar investments and cash and cash equivalents holdings.

#### *External research and development fees*

External research and development expenses increased from a recovery of \$29,961 to an expense of \$4,280,330 or 14,386% and increased from an expense of \$3,859,178 to \$6,083,378 or 58% for the three months and year ended December 31, 2024, respectively, compared to the equivalent periods in the prior year. During fiscal year of 2024, approximately 60% and 25% of

the research costs were incurred through the Huge Biopharma and FSD Australia entities, respectively. The major remaining costs were recorded under the Quantum entity, specifically relating to clinical trials conducted by ASPI Select to assess the efficacy of the unbuzzd™ product.

#### *Share-based payments*

Share-based payments decreased from \$99,384 to a reversal of \$82,477 and decreased from \$3,835,475 to \$152,214 or 96% for the three months and year ended December 31, 2024, respectively, compared to the equivalent periods in the prior year. Share-based payments expense changes based on the variability in the number of options granted, vesting periods of the options, the number of Performance Share Units (“PSUs”) granted, the number of RSUs granted, vesting periods of the PSUs and RSUs, number of warrants granted, vesting periods of the warrants, the grant date fair values of share-based awards, and share-based bonuses issued. During fiscal year 2024, smaller number of options were granted compared to fiscal year 2023. The majority of options granted in 2023 were canceled during the first nine months of the fiscal year 2024.

#### *Depreciation and amortization*

Depreciation and amortization decreased from \$122,217 to \$112,803 or 8% and decreased from \$2,506,316 to \$490,571 or 80% for the three months and year ended December 31, 2024, respectively, compared to the equivalent periods in the prior year. Depreciation and amortization in the current period related to the amortization of intellectual property and right-of-use assets. The decrease from prior year periods is due to the impairment of FSD-PEA and the Innovet license, resulting in lower amortization expense, as these assets were fully impaired during 2023.

#### *Impairment loss*

For the three months and year ended December 31, 2024, there was no impairment loss recognized.

For the three months ended December 31, 2023, the Company recognized an impairment loss of \$236,186 related to the note receivable as the likelihood of repayment of the note was considered remote. For the year ended December 31, 2023, the Company recognized an impairment loss of \$4,555,805 related to the impairment of the Prismic intangible assets following the decision to terminate the clinical trials of FSD-PEA and impairment of the Innovet intangible asset following the decision to no longer pursue the development of the ultra-micro PEA for veterinary purposes.

#### *Interest income*

Interest income decreased from \$153,791 to \$132,075 or 14% and decreased from \$786,363 to \$572,891 or 27% for the three months and year ended December 31, 2024, respectively, compared to the equivalent periods in the prior year. Interest income is primarily consisted of interest earned from the residential property investments through the FSD Strategic Investment entity.

#### *Other income*

Other income includes proceeds from the sale of excess inventory from research activities conducted by Unbuzzd. Other income was \$3,989 for the three months and year ended December 31, 2024, respectively, compared \$Nil in the equivalent periods in the prior year.

#### *(Gain) loss on settlement of debt*

During the three months and year ended December 31, 2024, the Company incurred a gain on settlement of debt of \$737,573 and \$732,417, respectively, related to the shares for debt transaction with arms-length creditors. The prices of shares issued to settled debts were different than the total amounts settled per agreement, thus resulting in gains and losses. The Company had incurred a loss on settlements of \$5,156, thereby reducing the gain on settlement during the last quarter of fiscal year 2024.

#### *Gain on remeasurement of financial liability*

For the three months and year ended December 31, 2024, the Company did not recognize a gain on remeasurement of financial liabilities.

For the three months and year ended December 31, 2023, the Company recognized a gain on remeasurement of financial liabilities of \$nil and \$4,939,015, respectively. For the year ended December 31, 2023, the gain is related to settlement reached with a Contract Research Organization.

#### *Loss (gain) on change in fair value of derivative liability*

In August 2020, the Company issued 42,499 Class B Subordinate Voting Shares and 21,249 warrants to purchase Class B Subordinate Voting Shares for total cash proceeds of \$9,999,997. Each warrant is exercisable to purchase one Class B Subordinate Voting Share of the Company at an exercise price of \$276.90 per share and expires five years from the date of issuance.

The fair value of the warrants liability as at December 31, 2024, was \$2, resulting in a gain on change in fair value of \$73 and gain of \$31,336 for the three months and year ended December 31, 2024, respectively.

The fair value of the warrants liability as at December 31, 2023, was \$31,338, resulting in a gain on change in fair value of \$99,045 and \$212,256 for the three months and year ended December 31, 2023.

During the year ended December 31, 2024, the Company issued convertible debentures which was treated as a hybrid financial instrument with derivative liability components. The Company issued 80,000 warrants pursuant to the convertible debenture. The fair value of the warrant liability as at December 13, 2024, the date of issuance was \$245,147. The fair value of the warrants as of December 31, 2024, was \$212,000 resulting in a gain on change in fair value of \$33,000.

#### *Unrealized loss on change in fair value of digital assets*

The Company's investments in digital assets are accounted for at fair value through profit or loss, resulting in loss or gain recognition as the fair value fluctuates.

#### *Loss on changes in fair value of investments*

The Company's various investments are accounted for at fair value through profit or loss, resulting in loss or gain recognition as the fair value fluctuates. The Company incurred loss on changes in fair value of \$3,702 for the year ended December 31, 2024. The following tables outline changes in investments during the year ended December 31, 2024:

Entity	Instrument	Balance at December 31, 2023 \$	Additions \$	Redemptions	Change in fair value through profit or loss \$	Effects of foreign exchange \$	Balance at December 31, 2024 \$
A2ZCryptoCap Inc.	Shares	6,049	—	—	(3,702)	(123)	2,224
Royal Bank of Canada	GIC	756,100	—	(738,000)	—	(18,100)	—
Royal Bank of Canada	GIC	—	2,955,610	(2,934,760)	—	—	20,850
Bank of Montreal	GIC	—	500,000	(500,000)	—	—	—
Meridian	GIC	—	3,234,026	(2,016,317)	—	(36,210)	1,181,499
		<b>762,149</b>	<b>6,689,636</b>	<b>(6,189,077)</b>	<b>(3,702)</b>	<b>(54,433)</b>	<b>1,204,573</b>
						<b>Current</b>	<b>1,202,349</b>
						<b>Non-Current</b>	<b>2,224</b>
							<b>1,204,573</b>

## SELECTED QUARTERLY INFORMATION

The following table sets forth selected unaudited quarterly statements of operations results for each of the eight quarters commencing January 1, 2024, and ended December 31, 2025. The information for each of these quarters has been prepared on the same basis as the audited annual financial statements for the year ended December 31, 2025. This data should be read in conjunction with the audited annual financial statements for the year ended December 31, 2025. These quarterly operating results are not necessarily indicative of our operating results for a full year or any future period.

	31-Dec-25 \$	30-Sep-25 \$	30-Jun-25 \$	31-Mar-25 \$	31-Dec-24 \$	30-Sep-24 \$	30-Jun-24 \$	31-Mar-24 \$
Interest income (expense)	(22,585)	100,420	90,733	67,216	132,075	163,868	104,424	172,524
Net loss for the period	3,703,032	4,747,600	9,766,327	8,739,881	5,456,278	4,015,327	3,352,499	2,091,425
Net loss per share - basic	0.97	1.25	3.23	3.53	2.89	4.37	0.08	0.05
Net loss per share - diluted	0.97	1.25	3.23	3.53	2.89	4.37	0.08	0.05

## SEGMENT INFORMATION

Reportable segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker, with appropriate aggregation. The chief operating decision maker is the CEO who is responsible for allocating resources, assessing the performance of the reportable segment and making key strategic decisions. The Company operated in two segments: Biopharmaceutical and Strategic Investments.

The Company's Biopharmaceutical segment is focused on furthering the research and development of the Company's drug candidates and the development of a treatment for alcohol misuse for application in hospitals and other medical practices.

The Company's Strategic Investments segment was focused on generating returns and cash flow through the issuance of loans secured by residential property, with FSD Strategic Investments having a first or second collateral mortgage on the secured property.

The following tables summarize the Company's interest income, total operating expenses, and net loss for the years ended December 31, 2025, and 2024 on a segmented basis:

<b>As at December 31, 2025</b>			
	<b>Biopharmaceutical</b>	<b>Strategic Investments</b>	<b>Total</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>
Current assets	6,478,353	—	<b>6,478,353</b>
Non-current assets	4,682,556	—	<b>4,682,556</b>
Current liabilities	6,058,294	—	<b>6,058,294</b>

<b>As at December 31, 2024</b>			
	<b>Biopharmaceutical</b>	<b>Strategic Investments</b>	<b>Total</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>
Current assets	8,620,407	3,432,340	<b>12,052,747</b>
Non-current assets	5,066,477	—	<b>5,066,477</b>
Current liabilities	6,678,992	—	<b>6,678,992</b>
Non-current liabilities	—	—	<b>—</b>

<b>For the years ended December 31, 2025</b>			
	<b>Biopharmaceutical</b>	<b>Strategic Investments</b>	<b>Total</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>
Interest expense (income)	1,219	(237,303)	<b>(236,084)</b>
Total operating expenses	15,301,638	736	<b>15,302,374</b>
Net (loss) income	(27,193,407)	236,567	<b>(26,956,840)</b>

<b>For the years ended December 31, 2024</b>			
	<b>Biopharmaceutical</b>	<b>Strategic Investments</b>	<b>Total</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>
Interest expense (income)	(14,695)	(558,196)	<b>(572,891)</b>
Total operating expenses	16,135,899	361	<b>16,136,260</b>
Net (loss) income	(15,473,364)	557,835	<b>(14,915,529)</b>

## FINANCIAL POSITION

As at	December 31, 2025 \$	December 31, 2024 \$	Change \$	Change %
<b>ASSETS</b>				
<b>Current assets</b>				
Cash and cash equivalents	1,905,357	5,995,872	(4,090,515)	-68%
Other receivables	231,053	374,678	(143,625)	-38%
Prepaid expenses and deposits	15,290	69,036	(53,746)	-78%
Finance receivables, net	—	3,432,340	(3,432,340)	-100%
Investments	459,080	1,202,349	(743,269)	-62%
Inventory	52,133	117,242	(65,109)	-56%
Digital assets – restricted	1,601,865	—	1,601,865	100%
Digital assets	3,815,440	861,230	2,954,210	157%
	<b>6,478,353</b>	<b>12,052,747</b>	<b>(5,574,394)</b>	<b>-46%</b>
<b>Non-current assets</b>				
Equipment, net	67,029	76,894	(9,865)	-13%
Investments	—	2,224	(2,224)	-100%
Right-of-use asset, net	102,320	53,488	48,832	91%
Intangible assets, net	4,513,207	4,933,871	(420,664)	-9%
<b>Total assets</b>	<b>11,160,909</b>	<b>17,119,224</b>	<b>(5,958,315)</b>	<b>-35%</b>
<b>LIABILITIES</b>				
<b>Current liabilities</b>				
Trade and other payables	4,182,083	4,362,068	(179,985)	-4%
Lease obligations	103,165	53,780	49,385	92%
Warrants liability	—	212,002	(212,002)	-100%
Derivative liabilities	—	280,000	(280,000)	-100%
Deferred income	—	1,000,000	(1,000,000)	100%
Notes payable	1,300,549	619,029	681,520	110%
Convertible debentures	472,497	152,113	320,384	211%
	<b>6,058,294</b>	<b>6,678,992</b>	<b>(620,698)</b>	<b>-9%</b>
<b>Total liabilities</b>	<b>6,058,294</b>	<b>6,678,992</b>	<b>(620,698)</b>	<b>-9%</b>
<b>SHAREHOLDERS' EQUITY</b>				
Class A share capital	152,247	151,701	546	0%
Class B share capital	169,551,044	150,318,624	19,232,420	13%
Warrants	10,009	1,997,759	(1,987,750)	-99%
Contributed surplus	35,405,812	31,072,543	4,333,269	14%
Foreign exchange translation reserve	91,533	50,795	40,738	80%
Accumulated deficit	(198,286,170)	(172,110,884)	(26,175,286)	15%
<b>Equity attributable to shareholders of the Company</b>	<b>6,924,475</b>	<b>11,480,538</b>	<b>(4,556,063)</b>	<b>-40%</b>
<b>Non-controlling interests</b>	<b>(1,821,860)</b>	<b>(1,040,306)</b>	<b>(781,554)</b>	<b>75%</b>
	<b>5,102,615</b>	<b>10,440,232</b>	<b>(5,337,617)</b>	<b>-51%</b>
<b>Total liabilities and shareholders' equity</b>	<b>11,160,909</b>	<b>17,119,224</b>	<b>(5,958,315)</b>	<b>-35%</b>

## Assets

Cash and cash equivalents decreased by \$4,090,515, or 68% to \$1,905,537 as at December 31, 2025, compared to December 31, 2024, driven by:

- Operating outflows of \$8.2 million, reflecting the net loss and working capital changes;
- Investing outflows of \$2.0 million, reflecting digital asset-related outflows; and
- Financing inflows \$6.1 million, mainly from convertible debenture proceeds, finance receivable liquidation, and proceeds from various loans.

Other receivables decreased by \$143,625 or 38%, primarily due to timing differences in sales tax refunds from the CRA and Australian tax authorities, alongside improved collection cycles.

Finance receivables decreased by \$3,432,340 or 100% for the year ended December 31, 2025. During the year ended December 31, 2025, the Company, through its subsidiary FSD Strategic Investments, sold its entire portfolio of loan receivables to a corporation owned by the CFO of the Company. The carrying amount of finance receivables sold was \$2,027,730. Total consideration received was \$1,824,203 and an interest receivable of \$85,788. This resulted in a realized loss on sale of \$117,136 recognized in the consolidated statements of loss and comprehensive loss. Following the sale, the Company has no further rights or obligations with respect to the sold portfolio.

Total digital assets increased by \$2,954,210 or 343%, driven by the Company's expansion of its cryptocurrency holdings during the year.

The right-of-use assets increased by \$48,832, or 91% as at December 31, 2025, due to a new lease acquisition for the Company office operations.

Intangible assets decreased by \$420,664, or 9% as at December 31, 2025, due to amortization expense of the Company's intangible asset for Lucid, representing the license agreement with University Health Network.

### Liabilities

Trade and other payables decreased by \$179,985 or 5%, driven by working capital management and timing of vendor payments.

Warrants liability decreased to \$Nil as at December 31, 2025 (December 31, 2024 - \$212,002) as all warrants related to the convertible debentures were exercised during the year ended December 31, 2025.

Derivative liabilities decreased to \$Nil as at December 31, 2025 (December 31, 2024 - \$280,000). The Company's convertible debentures were fully converted by December 31, 2025, reducing the balance to \$Nil (December 31, 2024 - \$280,000).

Deferred income decreased to \$Nil as at December 31, 2025 (December 2024 - \$1,000,000) as proceeds from the Sports Coat Prepaid Purchase Agreement were recognised as other income during the year ended December 31, 2025.

Convertible debentures increased to \$472,497 as at December 31, 2025 (December 2024 - \$152,113), entirely attributable to the convertible debentures issued by Unbuzzd. The Company's convertible debentures were fully converted by December 31, 2025, reducing the balance to \$Nil (December 31, 2024 - \$152,113).

### Shareholders' equity

Shareholder's equity decreased by \$4,556,063 primarily due to:

- (i) a decrease of \$1,987,750 related to warrants expired during the year;
- (ii) a decrease of \$26,956,840 related to net loss for the year; and
- (iii) an increase of \$19,232,420 related Class B shares issued pursuant to the conversion of debentures and issuance of shares upon exercise of options, warrants and settlement of debt.

### Non-controlling interests

Through the License Agreement, Quantum acquired 34.66% of Unbuzzd on July 31, 2023. As of December 31, 2025, the Company has a 19.84% (December 31, 2024 – 22.95%) ownership interest in Unbuzzd through Unbuzzd Common Shares. The non-controlling interest represents the Unbuzzd Common Shares not attributable to the Company.

Reconciliation of non-controlling interest is as follows:

	\$
<b>Balance, December 31, 2023</b>	(327,501)
Net loss for the year	(712,805)
<b>Balance, December 31, 2024</b>	(1,040,306)
Net loss for the year	(781,554)
<b>Balance, December 31, 2025</b>	<b>(1,821,860)</b>

The consolidated financial statements incorporate the assets and liabilities of Unbuzzd as of December 31, 2025.

## **LIQUIDITY, CAPITAL RESOURCES AND FINANCING**

The general objectives of our capital management strategy are to preserve our capacity to continue operating, provide benefits to our stakeholders and provide an adequate return on investment to our shareholders by continuing to invest in our future that is commensurate with the level of operating risk we assume. We determine the total amount of capital required consistent with risk levels. This capital structure is adjusted on a timely basis depending on changes in the economic environment and risks of the underlying assets. We are not subject to any externally imposed capital requirements.

The financial statements and this MD&A have been prepared on the basis of accounting principles applicable to a going concern, which assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. In making this assessment, management concluded that it has sufficient working capital as of December 31, 2025, to carry out its planned operations over the next twelve months.

### ***Cash flows for the years ended December 31, 2025, and 2024***

#### ***Cash Flows (Used in) Operating Activities***

For the year ended December 31, 2025, cash used in operating activities was \$8,237,012, compared to \$6,876,479 in the prior year. The increase in cash outflows of approximately \$1.36 million was primarily driven by a higher net loss of \$26.9 million (2024 - \$14.9 million). This loss was significantly adjusted for several large non-cash items, including:

- \$11.91 million non-cash loss from the increase in the fair value of derivative liabilities;
- \$2.95 million in share-based payments; and
- \$1.49 million loss on the issuance of convertible debt.

These non-cash losses were partially offset by non-cash gains, including realized gains on the sale of digital assets and investments of \$0.59 million and \$0.18 million, respectively, and a gain on the change in fair value of investments of \$0.26 million.

Changes in working capital for the year provided a net source of cash of approximately \$1.95 million, which helped mitigate the operating loss. Significant working capital movements included the following:

- Finance Receivables: Provided \$1.49 million in cash, resulting from the entire sale of the loan receivable portfolio.
- Trade and Other Payables: Provided \$1.17 million in cash, primarily due to the timing of vendor payments and accrued liabilities.
- Deferred Income: The previously recorded amount of \$1 million as deferred income related to the Sports Coat Prepaid Purchase Agreement, was reversed during FY2025 resulting in a \$1 million deduction in the working capital adjustment, as the funds were already received during the prior year in FY2024.

#### ***Cash Flows (Used in) Provided by Investing Activities***

For the year ended December 31, 2025, cash used in investing activities was \$1,952,469, compared to \$1,503,559 in the prior year. The increase in cash outflows of approximately \$0.45 million reflects a strategic shift in the Company's asset composition, moving from traditional investments to digital assets.

During the year ended December 31, 2025, the Company continued to execute its strategy of acquiring and holding digital assets, with gross purchases totaling \$5,632,576, representing the most significant investing use of cash. The Company sold a portion of its digital asset holdings, generating proceeds of \$2,500,425. This resulted in a net cash outflow of \$3,132,151 for digital asset activities during the year ended December 31, 2025.

As at December 31, 2025, the fair value of the Company's digital asset holdings was \$3,815,440, compared to \$861,230 at the end of 2024, representing an increase of \$2,954,210. The difference between the net cash deployed (\$3,132,151) and the

increase in carrying value (\$2,954,210) is explained by the accounting recognition of gains and losses on the portfolio during the year:

- The Company realized a gain of \$593,922 on the sale of digital assets, which is reflected in the proceeds received.
- An unrealized loss of \$771,863 was recognized in the statement of loss and comprehensive loss, reflecting the decline in fair value of the assets held at year-end relative to their cost.

The net effect of these realized and unrealized amounts was a negative \$177,941 fair value adjustment, which accounts for the variance between the net cash invested in digital assets during the year and the net increase reflected on the balance sheet.

#### **Cash Flows Provided by Financing Activities**

Financing activities generated cash flows of \$6,098,966 for the year ended December 31, 2025, compared \$11,618,870 in the corresponding period of 2024. The Company raised capital through equity financing in 2024 compared to debt instruments and loans in 2025. The primary sources of cash in the current period were:

1. \$3.2 million from the issuance of convertible debentures;
2. \$1.5 million in proceeds from other loans received in Huge Biopharma and FSD Australia.
3. \$1.8 million in proceeds from sale of finance receivables, which corresponded to the cash consideration portion of the entire sale of loan receivables to a related party.
4. \$0.3 million in proceeds from issuance of shares related to the at-the-market offering agreement with Rodman.

These inflows were partially offset by other loan repayments totalling \$0.8 million.

#### **CONTRACTUAL OBLIGATIONS**

We have no significant contractual arrangements other than those noted in our financial statements.

#### **OFF-BALANCE SHEET ARRANGEMENT**

We have no off-balance sheet arrangements other than those noted in our financial statements.

#### **TRANSACTIONS WITH RELATED PARTIES**

Related parties and related party transactions impacting the accompanying financial statements are summarized below and include transactions with the following individuals or entities:

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company directly or indirectly, including any directors (executive and non-executive) of the Company.

Transactions with key management and directors comprise the following:

- a) Director's compensation for the year ended December 31, 2025, was \$121,713 (2024 - \$161,048 and 2023 - \$175,140).
- b) During the year ended December 31, 2025, the Company granted 120,692 options to officers and employees of the Company, each with exercise prices ranging from C\$6.60 to C\$24.50 and expiring 2-5 years from the date of issuance.
- c) During the year ended December 31, 2023, the Company entered into a secured loan agreement with the CEO for C\$1,200,000, with monthly payments of C\$6,000 based on an annual interest rate of 6%. The loan had a maturity date of April 26, 2025, and was part of FSD Strategic Investments' portfolio of finance receivables. During the year ended December 31, 2024, a payment of C\$400,000 was made by the CEO, and monthly payments were subsequently reduced to C\$4,000. During the year ended December 31, 2025, the CEO made a payment of C\$800,000 towards the loan, thereby settling the total debt outstanding owed to FSD Strategic Investments.
- d) During the year ended December 31, 2025, the Company accrued management bonuses of \$645,570.
- e) During the year ended December 31, 2024, the Company granted 23,000 options to officers and employees of the Company each with exercise prices ranging from C\$5.25 to C\$5.60 and expiring two years from date of issuance.
- f) During the year ended December 31, 2024, the Company cancelled 30,768 options held by officers and employees of the company. They issued RSU of 30,768 in replacement of the cancelled options.
- g) During the year ended December 31, 2024, the Company granted the Co-Chairman of the board, the CEO and the current CFO total shares of 248,160 with a fair value of \$1,017,456 as bonus for the year.
- h) On August 15, 2024, the Company closed a non-brokered private placement and issued 4 Class A Multiple Voting Shares at a price of C\$18 per Class A Multiple Voting Share for aggregate gross proceeds of C\$72 to two non-arm's length parties, with each entity receiving 2 Class A Multiple Voting Shares. On September 13, 2024, the Company closed a non-brokered private placement and issued 6 Class A Multiple Voting Shares at a price of \$6 per Class A

Multiple Voting Share for gross proceeds of C\$36 to the same two non-arm's length parties, with each entity receiving 3 Class A Multiple Voting Shares.

- i) On December 10, 2025, the Company closed a non-brokered private placement and issued 30 Class A multiple Voting Shares at a price of C\$25 per Class A Multiple Voting Share for aggregate gross proceeds of C\$750 to two non-arm's length parties, with each receiving 15 Class A Multiple Voting Shares.
- j) During the year ended December 31, 2025, the Company, through its subsidiary FSD Strategic Investments, sold its entire portfolio of loan receivables to a corporation owned by the CFO of the Company.
- k) During the year ended December 31, 2025, the Company entered into a lease agreement with Peak Corp, an entity in which a director is a family member of a senior officer of the Company. This lease arrangement resulted in the right-of-use asset recognized as at December 31, 2025, of \$102,320. The lease term ends June 30, 2027.

Key management personnel compensation during the years ended December 31, 2025, 2024, and 2023 is comprised of:

	2025	2024	2023
	\$	\$	\$
Salaries, benefits, bonuses and consulting fees	1,501,380	908,052	1,395,096
Share-based payments	1,994,558	1,085,669	1,980,732
	<b>3,495,938</b>	<b>1,993,721</b>	<b>3,375,828</b>

As at December 31, 2025, the Company has \$645,570 owing to related parties related to bonus accruals included in accounts payable and accrued liabilities (December 31, 2024 - \$Nil).

## FINANCIAL INSTRUMENTS AND OTHER INSTRUMENTS

### *Credit risk*

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from deposits with banks and outstanding other receivables and finance receivables. The Company trades only with recognized, creditworthy third parties.

The Company does not hold any collateral as security for its outstanding finance receivables but mitigates this risk by dealing only with, what management believes to be, financially sound counterparties and, accordingly, does not anticipate significant loss for non-performance. The loans are secured by residential properties, and the Company is granted a first or second collateral charge mortgage on the properties for a sum equal to the interest payments plus the principal amount. The Company performs assessments on factors such as timing of payments, loan to value ratios, communications with the borrower and external macro factors such as interest rates and economic conditions to mitigate risks.

### *Liquidity risk*

Liquidity risk is the risk the Company will not be able to meet its financial obligations as they come due. The Company's exposure to liquidity risk is dependent on the Company's ability to raise additional financing to meet its commitments and sustain operations. The Company mitigates liquidity risk by management of working capital, cash flows, the issuance of share capital and if desired, the issuance of debt. The Company's trade and other payables are all due within twelve months from the date of these financial statements.

If unanticipated events occur that impact the Company's ability to carry out the planned clinical trials, the Company may need to take additional measures to increase its liquidity and capital resources, including issuing debt or additional equity financing or strategically altering the business forecast and plan. In this case, there is no guarantee that the Company will obtain satisfactory financing terms or adequate financing. Failure to obtain adequate financing on satisfactory terms could have a material adverse effect on the Company's results of operations or financial condition.

### *Market risk*

Market risk is the risk the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risk: foreign currency risk, interest rate risk and other price risk.

- Foreign currency risk

Foreign currency risk arises on financial instruments that are denominated in a currency other than the functional currency in which they are measured. The Company's primary exposure with respect to foreign currencies is from Canadian dollar denominated cash and trade and other payables. A 1% change in the foreign exchange rates would not result in any significant impact to the financial statements.

- Interest rate risk

Interest rate risk is the risk the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's finance receivables are at fixed rates and there are no material long-term borrowings outstanding. The Company is not exposed to interest rate risk as at December 31, 2025.

- Other price risk

Other price risk is the risk the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in the market. The Company is not exposed to other price risk as at December 31, 2025.

#### *Fair values*

The carrying values of cash, other receivables, trade and other payables and notes payable approximate fair values due to the short-term nature of these items or they are being carried at fair value or, for notes payable, interest payables are close to the current market rates. The risk of material change in fair value is not considered to be significant. The Company does not use derivative financial instruments to manage this risk.

Financial instruments recorded at fair value on the consolidated statement of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The Company categorizes its fair value measurements according to a three-level hierarchy. The hierarchy prioritizes the inputs used by the Company's valuation techniques. A level is assigned to each fair value measurement based on the lowest-level input significant to the fair value measurement in its entirety. The three levels of the fair value hierarchy are defined as follows:

- Level 1 – Unadjusted quoted prices as at the measurement date for identical assets or liabilities in active markets.
- Level 2 – Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
- Level 3 – Significant unobservable inputs that are supported by little or no market activity. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

The fair value hierarchy requires the use of observable market inputs whenever such inputs exist. A financial instrument is classified to the lowest level of the hierarchy for which a significant input has been considered in measuring fair value.

Private company investments measured at fair value are classified as Level 3 financial instruments. The valuation method and significant assumptions used to determine the fair value of private company investments have been disclosed in the financial statements. The Company did not hold any private company investments as of December 31, 2025. During the year, there were no transfers of amounts between levels.

#### **CRITICAL ACCOUNTING POLICIES AND ESTIMATES**

Refer to Note 2 and Note 3 of the audited consolidated financial statements for the fiscal year ended December 31, 2025, for a full discussion of our critical accounting policies and estimates.

#### **OUTSTANDING SHARE DATA**

The Company is authorized to issue an unlimited number of Class A Multiple Voting Shares and an unlimited number of Class B Subordinate Voting Shares, all without par value. All shares are ranked equally with regards to the Company's residual assets.

The Class B Subordinate Voting Shares are "restricted securities" within the meaning of such term under applicable Canadian securities laws, as these securities do not carry equal voting rights as compared with the Class A Multiple Voting Shares.

The holders of Class A Multiple Voting Shares are entitled to 276,660 votes per Class A Multiple Voting Share held. Class A Multiple Voting Shares are held by the CEO, President, Co-Chairman of the Board and the Director, Co-Chairman of the Board.

The Company's outstanding capital was as follows as at the date of this MD&A:

Class A Multiple Voting Shares	42 <sup>(1)</sup>
Class B Subordinate Voting Shares	5,829,223 <sup>(1)</sup>
Share options	160,956
RSUs	1,600
Warrants	0

**Note:**

1. The Class A Multiple Voting Shares represent approximately 66.59% of the voting rights attached to Quantum's outstanding voting securities.

As of the date of this MD&A, the Company had 5,829,223 Class B Subordinate Voting Shares issued and outstanding. The ownership was distributed as follows:

1. 4,953,895 Class B Subordinate Voting Shares, or 84.9%, were held through depository nominees (CEDE & Co. and CDS & Co.) on behalf of The Depository Trust & Clearing Corporation; and
2. 875,328 Class B Subordinate Voting Shares, or 15.1%, were held by registered holders with the Company's transfer agent.

**DISCLOSURE CONTROLS AND PROCEDURES AND INTERNAL CONTROLS OVER FINANCIAL REPORTING**

**A. Disclosure Controls and Procedures**

We maintain disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of our CEO and CFO, our management has evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2025, the end of the period covered by this report. Based on that evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of December 31, 2025.

The effectiveness of our disclosure controls and procedures and our internal control over financial reporting is subject to various inherent limitations, including cost limitations, judgments used in decision making, assumptions about the likelihood of future events, the soundness of our systems, the possibility of human error, and the risk of fraud. Moreover, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions and the risk that the degree of compliance with policies or procedures may deteriorate over time. Because of these limitations, there can be no assurance that any system of disclosure controls and procedures or internal control over financial reporting will be successful in preventing all errors or fraud or in making all material information known in a timely manner to the appropriate levels of management.

**B. Management's Report on Internal Control over Financial Reporting**

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is the process designed by and under the supervision of our CEO and CFO to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of our financial statements for external reporting in conformity with the International Financial Reporting Standards as issued by the International Accounting Standards Board. Management has evaluated the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013).

Under the supervision and with the participation of our CEO and CFO, our management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2025, and concluded that it was effective.